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Abstract 
The Roux-en-Y Gastric Bypass (RYGB) operation for obesity results in 
sustained weight loss and improvements in carbohydrate tolerance, that 
no current medical treatment can replicate. The mechanism that underlies 
the metabolic improvements observed after RYGB remains unclear, but 
there is an association with increased post-prandial concentrations of 
several gut hormones; glucagon like peptide-1 (GLP-1), oxyntomodulin 
(OXM), peptide YY (PYY) and glucagon. Each of these hormones have 
multiple and different actions that include reductions in food intake, 
increases in energy expenditure, satiety and improvements in glucose 
tolerance.  Previous studies investigating the metabolic effects of these 
hormones have used single or dual infusions. 
 
In this thesis, I have investigated for the first time the effect of co-
infusing three gut hormones; GLP-1, OXM and PYY together on food 
intake. The dose used of each hormone was designed to replicate the 
postprandial levels observed after RYGB. This triple hormone infusion 
resulted in a significant reduction in food intake relative to saline and 
subsequently supports the role of gut hormones in the metabolic benefits 
observed after RYGB  
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In addition, I have also investigated the effect of co-infusing GLP-1 and 
glucagon on carbohydrate tolerance. Glucagon is elevated post RYGB 
but is known to increase plasma glucose by promoting glycogenolysis 
and gluconeogenesis This conflicts with the improved glucose tolerance 
observed post RYGB. I have demonstrated for the first time that co-
infusion of GLP-1 and glucagon results in improved glucose tolerance. 
  
Finally, I have investigated a metabolic complication of RYGB in which 
gut hormones have been implicated, postprandial hypoglycaemia (PPH). 
In this thesis, I have shown an association between PPH and elevated 
GLP-1 and glucagon. These data provide a potential target for treating 
PPH as well as demonstrating a potential adverse event of elevated gut 
hormone concentrations. 
 
 
 
 
 
 
 4 
Copyright Declaration 
‘The copyright of this thesis rests with the author and is made 
available under a Creative Commons Attribution Non-Commercial 
No Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do 
not use it for commercial purposes and that they do not alter, 
transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work’ 
  
  
 5 
Declaration of Originality 
I declare that the text is of my own writing. Where appropriate I have 
cited other researchers’ work. 
The majority of the work described in this thesis was done myself.All 
collaboration and assistance is detailed below. 
Chapter 2 Human studies were performed in collaboration with Dr 
Rachel Troke, Dr Jaimini Cegla Dr Katherine McCullough and Dr Ben 
Field. Assistance with radioimmunoassays was performed by Dr Jaimini 
Cegla and Dr Ben Jones. 
Chapter 3 Human studies were performed collaboration with Dr 
Preeshila Behary, Dr Nicola Guess and Miss Werd Al-Najim. Assistance 
with assays was performed by Dr Preeshila Behary and Dr Nicolai 
Albrechsten. 
Chapter 4 Human studies were performed in collaboration with Dr 
Preeshila Behary. Assistance with assays was performed by Dr Preeshila 
Behary.  
 
 
 
 
 
 
 
 6 
Acknowledgements 
I would like to thank Prof Bloom for giving me the opportunity to the 
research presented in this thesis. I am also grateful for my supervisors Dr 
Niamh Martin and Prof Tricia Tan. Their continuing support and 
guidance has been invaluable to me and will always be remembered. 
Thanks to the collaborators and in particular Dr Preeshila Behary who 
often stayed late with me.   
  
 7 
Abbreviations 
α-MSH α-Melanocytes Stimulating Hormone 
ADRR Average daily risk 
AgRP  Agouti-Related Protein 
ANOVA Analysis of Variance 
AP   Area postrema 
ARC  Arcurate Nucleus 
ATP  Adenosine triphosphate 
AUC   Area under the curve 
BAT  Brown adipose tissue 
BMI  Body Mass Index 
CART Cocaine and amphetamine regulated transcript 
CNS  Central Nervous System 
CONGO Continuous overlapping net glycaemic action 
DEBQ Dutch Eating Behaviour Questionnaire 
DIO  Diet Induced Obesity 
DMN  Dorsomedial Nucleus 
DMV  Dorsal motornucleus of the vagus nerve 
DPP-4 Dipeptidyl Peptidase IV 
DVC  Dorsal vagal complex 
ELISA Enzyme-linked Immunosorbent Assay 
FGF  Fibroblast Growth Factor 
GI  Gastrointestinal 
GIP  Glucose-dependent insulinotropic peptide 
GLP-1 Glucagon-like Peptide-1 
GLP-1R Glucagon-like Peptide-1 Receptor 
GPCR G-protein-coupled receptor 
GRPP  Glicentin-related polypeptide 
HbA1c Glycated Haemoglobulin 
HBGI  High blood glucose index 
IP  Intraperitoneal 
IP  Intervening Peptide 
IP-1  Intervening Peptide-1 
IP-2  Intervening Peptide-2 
IV  Intravenous 
IGTT  Intravenous glucose tolerance test 
LBGI  Low blood glucose index 
LH  Lateral hypothalamus 
MAGE Mean amplitude glucose excursion 
MC4R melanocortin-4 receptor 
 8 
ME  Median Eminence 
MODD Mean of daily differences 
MPGF Major pro-glucagon fragment 
NICE  National Institute of Clinical Excellence 
NEFA Non-esterified fatty acids 
NPY  Neuropeptide Y 
NTS  Nucleus Tract Solitaris 
OXM  Oxyntomodulin 
PC  Prohormone Convertase 
POMC Propiomelamocortin 
PPH  Postprandial Hypoglycaemia  
PVN  Periventricular Nucleus 
PWL  Percentage weight loss 
PYY  Peptide YY 
RIA   Radioimmunoassay 
RCT  Randomised Controlled Study 
RYGB Roux-en Y Gastric Bypass 
SC  Subcutaneous 
SGLT1 Sodium Glucose Transport protein 1 
SEM  Standard error of the mean 
SON  Supraoptic Nucleus 
SOS  Swedish Obesity Subject 
T1DM Type one diabetes mellitus 
T2DM Type two diabetes mellitus 
UK  United Kingdom 
USA  United States of America 
VAS  Visual Analogue Scale 
VLED Very low energy diet 
  
 9 
Table of Contents 
THE ROLE OF GUT HORMONES ON FOOD INTAKE AND CARBOHYDRATE TOLERANCE
 ............................................................................................................................. 1 
ABSTRACT ............................................................................................................. 3 
COPYRIGHT DECLARATION .................................................................................... 5 
DECLARATION OF ORIGINALITY ............................................................................. 6 
ACKNOWLEDGEMENTS ......................................................................................... 7 
ABBREVIATIONS.................................................................................................... 8 
TABLE OF CONTENTS ........................................................................................... 10 
INDEX OF FIGURES .............................................................................................. 15 
INDEX OF TABLES ................................................................................................ 17 
CHAPTER 1: GENERAL INTRODUCTION ................................................................ 18 
1.1 Obesity – a pandemic .............................................................................................................................. 19 1.1.1 Central control of energy balance .............................................................................................................. 19 1.1.2 The health burden of obesity ....................................................................................................................... 21 
1.2 Treatment of obesity ............................................................................................................................... 21 1.2.1 Lifestyle modification ...................................................................................................................................... 21 
 10 
1.2.2 Pharmacotherapy .............................................................................................................................................. 22 1.2.3 Bariatric Surgery ............................................................................................................................................... 25 
1.3 Gut hormones ............................................................................................................................................ 29 1.3.1 Glucagon ................................................................................................................................................................ 30 1.3.2 Glucagon-like peptide-1 (GLP-1)  ............................................................................................................. 34 1.3.3 OXM ......................................................................................................................................................................... 43 1.3.4 Peptide YY (PYY) ............................................................................................................................................... 47 1.3.5 Evidence that gut hormones are important in weight loss after RYGB ..................................... 54 
1.4 Postprandial Hypoglycaemia- a metabolic complication of RYGB surgery ........................ 55 1.4.1 Incidence of PPH ................................................................................................................................................ 56 1.4.2 Pathogenesis of PPH ........................................................................................................................................ 56 
1.5 Aim of Studies ............................................................................................................................................ 58 
1.6 Hypotheses ................................................................................................................................................. 59 
CHAPTER 2: THE ACUTE EFFECTS OF CO-INFUSION OF GLUCAGON AND GLP-1 ON 
CARBOHYDRATE TOLERANCE IN HUMANS ........................................................... 60 
2.1 Introduction ............................................................................................................................................... 61 
2.2 Hypothesis and aims ............................................................................................................................... 65 2.2.1 Hypothesis ............................................................................................................................................................ 65 2.2.2 Aim ........................................................................................................................................................................... 65 
2.3 Materials and Methods ........................................................................................................................... 66 2.3.1 Peptides ................................................................................................................................................................. 66 2.3.2 Subjects .................................................................................................................................................................. 66 2.3.3 Protocol.................................................................................................................................................................. 68 2.3.4 Plasma Hormone and Other Assays .......................................................................................................... 71 
 11 
2.3.5 Statistical Analysis ............................................................................................................................... 74 
2.4 Results .......................................................................................................................................................... 75 2.4.1 Gut hormone assays ......................................................................................................................................... 75 2.4.2 Glucose and Insulin results ........................................................................................................................... 78 2.4.3 Measures of insulin sensitivity and insulin secretion ....................................................................... 84 2.4.4 Safety data ............................................................................................................................................................ 87 
2.5 Discussion ................................................................................................................................................... 93 
CHAPTER 3: THE ACUTE EFFECTS OF CO-INFUSION OF GLP-1, OXYNTOMODULIN 
AND PYY ON FOOD INTAKE AND NAUSEA ............................................................ 98 
3.1 Introduction ............................................................................................................................................... 99 
3.2 Hypothesis and aims ............................................................................................................................ 101 3.2.1 Hypothesis .......................................................................................................................................................... 101 3.2.1 Aim ......................................................................................................................................................................... 101 
3.3 Methods .................................................................................................................................................... 102 3.3.1 Peptides ............................................................................................................................................................... 102 3.3.2 Subjects ................................................................................................................................................................ 103 3.3.3 Protocol................................................................................................................................................................ 103 3.3.4 Blood assay analysis....................................................................................................................................... 107 3.3.5 Statistical analysis ........................................................................................................................................... 108 
3.4 Results ....................................................................................................................................................... 109 3.4.1 Dose finding study investigating the acute effects of GLP-1, OXM and PYY on energy intake and nausea in humans. ............................................................................................................................... 109 3.4.2 Investigation of the acute effects of subcutaneous co-administration of GLP-1, OXM and PYY on food intake and nausea. ........................................................................................................................... 120 
3.5 Discussion ................................................................................................................................................ 133 
 12 
CHAPTER 4: THE ROLE OF GUT HORMONES IN THE PATHOPHYSIOLOGY OF 
POSTPRANDIAL HYPOGLYCAEMIA ...................................................................... 136 
4.1 Introduction ............................................................................................................................................ 137 
4.2 Hypothesis and Aims ............................................................................................................................ 140 4.2.1 Hypothesis .......................................................................................................................................................... 140 4.2.2 Aims ....................................................................................................................................................................... 140 
4.3 Methods .................................................................................................................................................... 141 4.3.1 Subjects ................................................................................................................................................................ 141 4.3.2 Continuous Glucose Monitoring ............................................................................................................... 142 4.3.3 Mixed Meal Test (MMT) Study .................................................................................................................. 146 4.3.4 Prolonged Oral Glucose Tolerance Test (POGTT) ............................................................................ 147 4.3.5 Glucose, Insulin and C-peptide assays ................................................................................................... 147 4.3.6 Gut Hormone assays ...................................................................................................................................... 148 4.3.7 Statistical Analysis .......................................................................................................................................... 148 
4.4 Results ....................................................................................................................................................... 149 4.4.1 Demographics of subjects ............................................................................................................................ 149 4.4.1 Investigation into glycaemic variability in patients with PPH .................................................... 152 4.4.2. Comparison of changes in glucose and insulin following a Mixed Meal Test in patients suspected of having PPH ......................................................................................................................................... 154 4.4.3 Investigation into changes in glucose and insulin in PPH patients: Hypo vs Non-Hypo groups .............................................................................................................................................................................. 158 4.4.3 Investigation into changes in gut hormones in PPH patients: Hypo vs Non-Hypo groups............................................................................................................................................................................................. 163 4.4.4 Investigation into changes in glucose and insulin following a POGTT in patients with PPH.............................................................................................................................................................................................. 166 4.4.5 Investigation into changes in gut hormones following a POGTT in patients with Hypo and without Hypo during the test ................................................................................................................................ 169 
 13 
4.5 Discussion ................................................................................................................................................ 171 4.5.1 Increased Glycaemic Variability ............................................................................................................... 172 4.5.2 Altered glucose tolerance in patients post RYGB measured by a MMT .................................. 174 4.5.3 Differences in glucose, insulin and gut hormones, between RYGB patients who have biochemical hypoglycaemia and those that do not, during a MMT ...................................................... 176 4.5.4 Comparison of glucose, insulin and gut hormone responses between a MMT and POGTT in patients with PPH. ................................................................................................................................................. 179 
CHAPTER 5: GENERAL DISCUSSION ..................................................................... 184 
5.1 Co-infusion of GLP-1 and glucagon on carbohydrate tolerance in man. ........................... 189 
5.2 Combining gut hormones as treatment for obesity .................................................................. 193 
CHAPTER 6: APPENDIX ....................................................................................... 198 
6.1 Appendix 1- VAS ..................................................................................................................................... 199 
6.2.Appendix 2- Magpix Protocol............................................................................................................ 201 
References ....................................................................................................................................................... 202 
 
  
 14 
Index of Figures 
Figure 1.1 The anatomy of the gastrointestinal tract following RYGB 
surgery.. ............................................................................................ 26 
Figure 1.2 Proglucagon cleavage.. ........................................................ 42 
Figure 2.1 Plasma active GLP-1 (A) and glucagon (B) concentrations 
after hormone infusion.. ................................................................. 77 
Figure 2.2 Effects of glucagon, GLP-1 and combination on glucose 
(A) and insulin (B) concentrations. ............................................... 81 
Figure 2.3 Effects of glucagon, GLP-1 and combined combination on  
mean AUC glucose (A) and mean AUC insulin (B) during 
infusion.. ........................................................................................... 83 
Figure 2.4 Cardiovascular parameters during infusion of GLP-1, 
glucagon and combination of both. ............................................... 89 
Figure 2.5 VAS results performed during acute infusion of GLP-1, 
glucagon or combination of both. .................................................. 92 
Figure 3.1 Protocol for dose finding study (A) and main study (B). 105 
Figure 3.2 Percentage reduction in food intake following 
subcutaneous administration of GLP-1 (A), OXM (B) and PYY 
(C) relative to saline.. .................................................................... 112 
Figure 3.3 Percentage reduction in food intake achieved by 
subcutaneous co-infusion of GLP-1 and  OXM at varying doses 
relative to saline.. ........................................................................... 115 
Figure 3.4 Effect of subcutaneous co-administration of GLP-1, OXM  
and PYY at varying doses on food intake. .................................. 118 
Figure 3.5 Energy intake following ad-libitum meal in human 
subjects. .......................................................................................... 121 
Figure 3.6 Change from baseline in visual analogue scale (VAS) 
scores in subjects. .......................................................................... 124 
Figure 3.7 Mean plasma concentration of GLP-1 (A), OXM (B) and 
PYY (CC) during infusion of GLP-1, OXM and PYY. ............. 127 
Figure 3.8 Comparison of changes in glucose (A) and insulin (B) 
following co-infusion of GLP-1, OXM and PYY. ...................... 129 
Figure 3.9 Changes in pulse rate (A), systolic (B) and diastolic (C) 
blood pressure following co-infusion of GLP-1, OXM and PYY 
relative to saline.. ........................................................................... 132 
Figure 4.1 Changes in plasma glucose (A) and serum insulin (B) 
following a mixed meal in patients suspected to have PPH, a non- 
surgical obese group and an asymptomatic RYGB group. ....... 156 
Figure 4.2 Changes in glucose (A) and insulin (B)  following a mixed 
meal test in patients with suspected  PPH. ................................. 161 
 15 
Figure 4.3 Changes in serum GLP-1 (A), glucagon (B), PYY (C) and 
GIP (D) following a mixed meal test. .......................................... 165 
Figure 4.4 Changes in glucose (A) and insulin (B) during a POGTT..
 ......................................................................................................... 167 
Figure 4.5 Changes in GLP-1 (A), glucagon (B), GIP (C) and PYY 
(D) following an oral glucose challenge.. .................................... 170    
 16 
Index Of Tables 
Table 1. Measures of glucose homeostasis during a mixed meal test 
following infusion of GLP-1, glucagon or a combination of both.
 ........................................................................................................... 86 
Table 3.1 Investigation of the effects of varying doses of subcutaneous 
infusions of GLP-1, OXM or PYY alone on nausea. ................. 113 
Table 3.2 Effect of different doses of combined subcutaneous 
infusions of GLP-1 and OXM on nausea. ................................... 116 
Table 3.3 Effect of subcutaneous co-infusions of GLP-1, OXM and 
PYY of varying doses on nausea. ................................................. 119 
Table 4.1 Measures of glycaemic variability. .................................... 145 
Table 4.2 Normal reference range for measures of glycemic 
variability. ...................................................................................... 146 
Table 4.3 Demographics of subjects in study. ................................... 150 
Table 4.4 Demographics of PPH subjects. ......................................... 151 
Table 4.5 Comparison of measures of glycaemic variability between 
patients with PPH and those without. ......................................... 153 
Table 4.6 Comparison of measures of glucose homeostasis following a 
mixed meal in symptomatic RYGB group, a non- surgical obese 
group and an asymptomatic RYGB group. ................................ 157 
Table 4.7 Prevalence of hypoglycaemia  and nadir glucose during 
either a MMT or POGTT............................................................. 160 
Table 4.8 Comparison of measures of glucose homeostasis following a 
mixed meal in PPH patients.. ....................................................... 162 
Table 4.9 Comparison of measures of glucose homeostasis following a 
POGGT in PPH patients. ............................................................. 168 
Table 4.10 Summary of  gut hormone changes in those that have 
biochemical hypoglycaemia following either a MMT or a 
POGTT. .......................................................................................... 171 
 
  
 17 
 Chapter 1       
 General Introduction 
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1.1 Obesity – a pandemic 
The rise in obesity represents a modern day pandemic. Its prevalence has 
doubled in the last 30 years from 5 and 8% of men and women 
respectively in 1980 to 10 and 14% in 2008(1).  
 
The rapid rise in obesity reflects a positive imbalance between energy 
intake and energy expenditure. However, the causes for this imbalance 
are multifactorial and represent a complex interplay between 
environmental factors, a genetic predisposition and changes in human 
behaviour. 
1.1.1 Central control of energy balance 
Energy balance is regulated at a central level, specifically the 
hypothalamus and brain stem. Multiple different processes are co-
ordinated at these centres. These include,  
• The homeostatic control of energy intake;   
• The processing of gustatory, visual and olfactory sensation;   
• Determination of the rewarding/emotional aspects of food;   
• Higher cortical functions involved in motivation and impulse control;   
• Control of energy expenditure through metabolic rate and activity.  
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In order to tightly regulate energy balance it is essential for these centres 
to receive information regarding the environment. Peripheral signals are 
conveyed via neural and humoral pathways. The latter is facilitated by 
specific areas of the brain where the blood brain barrier is incomplete. 
These include the area postrema (AP) and the median eminence (ME). 
The brainstem receives signals from the periphery via the AP, and 
visceral vagal afferents carrying signals from the gut. The hypothalamus 
is influenced by higher centres, the brainstem and by peripheral humoral 
signals via the ME. 
Particularly relevant to the regulation of energy balance is the arcuate 
nucleus of the hypothalamus (ARC). Within the ARC are two distinct 
sets of neurons with opposite functions. The lateral ARC is specific for 
anorexigenic neurons co-expressing pro-opiomelanocortin (POMC) and 
cocaine and amphetamine regulated transcript (CART) (2). POMC is 
processed to produce α-melanocyte stimulating hormone (α-MSH) that in 
turn activates the melanocortin-4 receptor (MC4R).  A further group of 
neurons in the medial ARC co-express neuropeptide Y (NPY) and agouti 
gene related peptide (AgRP) (3). These neurotransmitters stimulate food 
intake and energy seeking behaviour, i.e. they are ‘orexigenic’. In 
particular, AgRP acts to antagonise α-MSH at the MC4R. The balance of 
activity between these two groups of neurons regulates body weight via 
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the paraventricular nucleus (PVN). This in turn influences higher centres 
in the cerebral cortex that regulate food seeking behaviour, the 
hypothalamo-pituitary-thyroid axis and the sympathetic nervous system 
to regulate the body’s basal metabolic rate and resting energy 
expenditure(4).  
1.1.2 The health burden of obesity 
Obesity is associated with multiple co-morbidities. These include 
cancer(5), obstructive sleep apnoea(6), hypertension(7), 
hyperlipidaemia(8), type 2 diabetes mellitus (T2DM)(9). Whilst obesity 
in itself is a risk factor for cardiovascular disease(10), the addition of the 
latter co-morbidities increases morbidity and mortality through 
myocardial infarction and stroke(11).  
1.2 Treatment of obesity 
1.2.1 Lifestyle modification 
Lifestyle modification (diet and exercise) remains the initial treatment for 
obesity and diabetes as endorsed by multiple guidelines (12-14). Dietary 
changes can refer to both calorie restriction and/or specific macronutrient 
modification. There is evidence that calorie restriction in the form of very 
low energy diets can results in significant weight loss with associated 
improvements in glycaemia. A Very Low Energy Diet (VLED) is defined 
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as a diet of 800kcal/day or less. Lim et al demonstrated that a VLED for 
8 weeks  in 11 patients with T2DM resulted in significant weight loss 
(mean percentage weight loss of 15±1%) with concomitant improvements 
in fasting glucose, hepatic insulin sensitivity and plasma lipids relative to 
non diabetic controls(15). However, this was a small, short term  study 
and whether the observed improvements in diabetes can be maintained 
using this approach in the longer term remain unknown. Specifically, in 
terms of weight loss, a meta-analysis of VLED has shown a modest 
average percentage weight loss of 6.79% at 5 years(16). However, dietary 
modifications are noted to have high attrition rates. 
1.2.2 Pharmacotherapy 
The history of obesity pharmacotherapy is burdened by numerous 
medications that have been removed due to unfavourable side effect 
profiles. Subsequently, increased scrutiny has resulted in a limited 
armoury of treatments. Furthermore, there are discrepancies between the 
licensed anti-obesity medication in the United Kingdom (UK) and the 
United States of America (USA). In the UK, there remains only one 
licenced pharmocotherapeutic approved by the National Institute of 
Clinical Excellence (NICE); orlistat, whilst in the USA there are 4 
additional anti-obesity drugs. The current anti-obesity drugs are 
• Orlistat 
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• Lorcaserin 
• Phentermine/toperimate 
• Naltrexone/bupropion 
• Liraglutide 
1.2.2.1 Orlistat 
This a gastrointestinal lipase inhibitor that results in excretion of 30% of 
ingested fat and modest weight reduction(17). However, the use of 
orlistat is limited by considerable gastrointestinal side effects, such that 
only 10% of patients remain adherent after 1 year (18). 
1.2.2.2 Lorcaserin 
Lorcaserin is an agonist for 5-HT receptors on anorectic POMC neurones. 
Previous 5-HT agonists used as anti-obesity drugs include fenfluramine,  
which was subsequently withdrawn due to increased risk of valvular heart 
disease(19). This side effect is mediated via 5-HT2B. Lorcaserin avoids 
this adverse event by being specific to the 5-HT2C receptor(20). Relative 
to placebo, it achieves weight loss of 3.0-3.6% in phase 3 trials(21,22). In 
addition it has been reported to reduce glycated haemoglobin (HbA1c) by 
0.5% in T2DM(23). Whilst approved by the Federal Drugs Agency 
(FDA) in 2012, the European Medical Agency (EMA) has asked for 
further safety data prior to licensing. 
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1.2.2.3 Phentermine/topirimate 
Both topirimate and phentermine are powerful anti-obesity 
monotherapies but their use has been limited by serious side effects. 
Phentermine is an amphetamine mimetic. The weight loss actions of this 
drug are mediated through enhanced norepinephrine and dopaminergic 
stimulation of POMC neurons. Similar amphetamine based drugs were 
popular anti-obesity treatments in the Seventies but concerns regarding 
addiction resulted in their use only short term. Topirimate was developed 
an anti-epileptic medication but its effect on weight loss was noted during  
initial drug trials(24). However, dose limiting, neuropsychiatric 
symptoms have prevented further development as a monotherapy for 
obesity. The mechanism by which topirimate achieves weight loss 
remains unclear but is there is evidence for both orexigenic glutamate 
signalling and increased energy expenditure(25,26). 
Use of these drugs in combination is attractive for a number of reasons. 
Since each act via different mechanisms, their combined effect on weight 
loss is less likely to be diminished by compensatory mechanisms. 
Additionally, the side effects that occurred with the high doses needed to 
achieve weight loss may be attenuated by using lower doses of the 
individual drugs that in combination still yield significant weight loss. 
The FDA has licensed two separate doses of these agents in combination. 
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The lower dose of 7.5mg phentermine/46mg topirimate yields placebo 
subtracted weight loss of 6.6%(27). Doubling this dose increases weight 
loss to 9.3% but is only approved to those who lose insufficient weight on 
the lower dose preparation(28).  
1.2.2.4 Naltrexone/bupropion 
This is another combination drug, combining naltrexone (an opioid 
receptor antagonist) and buproprion (a mixed dopamine and 
norepinephrine reuptake inhibitor)(29,30). Both these drugs are used 
individually for the treatment of addiction; naltrexone being used for 
alcohol dependence and bupropion for smoking cessation. 
Phase 3 studies have demonstrated a 3.2-5.2% weight loss greater than 
placebo with a 0.5% reduction in HbA1c in T2DM(31-34). 
1.2.3 Bariatric Surgery 
Bariatric surgery is an umbrella term encompassing a variety of 
operations that manipulate the gastrointestinal tract to achieve weight 
loss. There are a variety of operations that are performed around the 
world, but the three most common are gastric banding, laparoscopic 
sleeve gastrectomy and the Roux-en-y gastric bypass (RYGB) 
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1.2.3.1 Weight loss after RYGB 
Two recent randomised controlled trials (RCTs) comparing bariatric 
surgery to intensive lifestyle changes have shown that RYGB results in 
significantly greater weight loss and improvement in diabetes(36,37). 
Weight loss is durable as evidenced by the Swedish Obesity Subject 
(SOS) study, a prospective controlled trial which demonstrated that 10 
years after RYGB, percentage weight loss (PWL) is maintained at 
25±11%(38). 
 
Whilst the rate of obesity and its co-morbidities rise, there are limited 
non-surgical treatments. RYGB is the most effective treatment for 
durable weight loss, it is not without cost or risk. A meta-analysis quoted 
a 30-day mortality of 1 in 200(39) . Furthermore, some patients are 
reluctant to have surgery despite the low mortality. There remains an 
urgent need for a nonsurgical intervention for obesity. Understanding 
how RYGB is so effective may result in new more effective treatments. 
 
The mechanisms underlying the metabolic improvements after RYGB 
remain unclear but multiple theories have been postulated. The most 
supported mechanism involves changes in the concentration of 
postprandial gut hormones (discussed in section 1.3). Other potential 
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drivers of weight change post RYGB include bile acids, Fibroblast 
Growth Factor (FGF) 19  and microbiota.  
 
Bile acids and FGF 19 are metabolic regulators of glucose and energy 
metabolism and are elevated post RYGB(40). Bile acids have the 
potential to stimulate GLP-1 release through TGR5 receptors, found on L 
cells of the small bowel(41).  Bile acids also regulate FGF 19 release in 
the gut, which have been shown to inhibit hepatic gluconeogenesis(42). 
 
RYGB has been shown to change the composition of gut microbiota in 
rodent models of bariatric surgery. Li et al. performed either RYGB or 
sham operations in 30 male Wistar (non-obese) rats, and collected stool 
samples after surgery. Gut microbiota analysis demonstrated that post 
surgery there was a decrease in Firmicutes and Bacteroidetes but an 
increase in Proteobacteria (43). Another study comparing gut microbiota 
in 10 diet induced obese (DIO) mice that underwent RYGB to sham 
operated mice replicated the increased prevalence of Proteobacteria. The 
same group went on to transfer the gut microbiota from RYGB mice to 
germ free mice via caecal contents. This resulted in a significant decrease 
in PWL of 5.0±1.8% after two weeks compared to germ free mice that 
were inoculated with gut microbiota from sham operated mice (44). 
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There have been two human studies assessing the effect of RYGB on gut 
microbiota. Zhang et al, examined the gut microbiota from three groups: 
RYGB operated, obese and normal weight. There were only three subjets 
per group. The RYGB operated group demonstrated a relative increase in 
Proteobacteria and decrease in Firmicutes post surgery, compared to the 
obese and normal weight volunteers. However, this small study had 
issues in methodology. Specifically, the post RYGB patients had their 
stool samples collected at different time points spread between 8-15 
months. Additionally the pattern of weight loss after RYGB was 
heterogeneous, with two patients continuing to lose weight whilst one had 
a plateau in their weight loss (45). The postulated mechanisms by which 
changes in gut microbiota contribute to weight loss post RYGB include, a 
reduction in systemic inflammation and changes in short chain free fatty 
acids production, which potentially lead to increased gut hormone 
production and reduced energy harvesting from substrates(46).  
 
1.3 Gut hormones 
Whilst the mechanism by which RYGB is so effective remains elusive, 
there is an associated increase in various gut hormones post-surgery. An 
understanding of how these hormones regulate energy balance may help 
us to design effective anti-obesity treatments 
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1.3.1 Glucagon 
Glucagon was first identified in the 1922 as a “hyperglycaemic factor of 
the pancreas” as part of studies investigating the effects of pancreatic 
extracts(47). It has emerged that glucagon has a key role not only in in 
glucose homeostasis, but also in energy balance, affecting both 
appetite(48) and energy expenditure(49). 
1.3.1.1 Processing from the pro-glucagon   
 
Pro-glucagon, the precursor of glucagon, was identified in 1983 by Bell 
et al(50). It consists of 160 amino acids and is expressed mainly in 
pancreatic α cells, in the gut L cells and in the CNS(51). Later studies 
have established that these cells exhibit differential posttranslational 
processing of this precursor to produce tissue specific hormones (Figure 
1.2)(52,53). 
1.3.1.2 Biological actions of glucagon 
1.3.1.2.1 Glucose metabolism 
The etymology of glucagon reveals its most well known function ie gluc 
and agon meaning sweet and to lead respectively. Glucagon increases 
plasma glucose levels via multiple mechanisms; 
• Promotes glycogenolysis 
• Inhibits glycogenesis 
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• Promotes gluconeogenesis 
• Inhibits glycolysis  
The net result of these effects is a rise in plasma glucose (54). 
1.3.1.2.2 Lipid metabolism 
Glucagon has two major actions on lipid metabolism. Firstly, chronic (21 
days) subcutaneous injection of glucagon in rats  results in a reduction of 
plasma cholesterol and triacylglycerol of 40 and 70%(55). The 
mechanism for this remains unclear but there is an associated increase in 
cholesterol transformation into bile acids(55). Alternatively, mouse 
studies have demonstrated that administration of glucagon to wild type 
mice resulted in an increase in beta oxidation of non-esterified fatty acids 
(NEFA). This effect  may account for the increase in plasma triglycerides 
observed in glucagon knock out mice (56). 
 
Glucagon also promotes promotes lipolysis in white adipocyte tissue(57). 
This is thought to relate to glucagon’s action on stimulating hormone 
sensitive lipase, which in turn increases NEFA (58). 
1.3.1.2.3 Food Intake 
Glucagon at physiological levels reduces food intake in rats(59) and 
men(60). The evidence for this is twofold. Firstly, portal infusions of 
glucagon antibodies administered to rats prior to a meal result in 
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glucagon antagonism and increased food intake(61). Secondly, an 
infusion of glucagon at a physiological dose in man resulted in a 
reduction in food intake(62). The mechanism for the observed anorectic 
action of glucagon may be via vagal afferent stimulation, specifically the 
hepatic branch, as selective hepatic vagotomy results in attenuation of 
glucagon satiety effect(63).  
1.3.1.2.4 Energy Expenditure 
In addition to its action as an anorectic hormone, glucagon also increases 
energy expenditure, suggesting a potential dual action on achieving 
weight loss.  
 
Glucagon role in increasing energy expenditure is supported by the 
observation of increased oxygen consumption in rats that were infused 
with pharmacological doses of glucagon(64).This increase in energy 
expenditure is thought to be mediated via brown adipose tissue (BAT), 
through uncoupling of the respiratory chain resulting in non-shivering 
thermogenesis. This is also supported by the observation that serum 
glucagon levels increase after cold exposure (a potent stimulator of 
BAT)(65).  
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Glucagon-stimulated increased oxygen consumption was blocked by the 
use of propranolol (a beta blocker) suggesting that glucagon exerts it 
effects on energy expenditure via the sympathetic nervous system(66). 
This is further supported by the observation that denervated BAT blunts 
thermogenesis induced by glucagon(67). 
 
However a recent study by Salam et al failed to show an increase in 
metabolic activity in BAT following a glucagon infusion in man, despite 
evidence of an increase in energy expenditure(68). This suggests that the 
effect of glucagon on energy expenditure is independent of BAT. An 
alternative mechanism for glucagon stimulated energy expenditure is 
futile substrate cycling, in which cyclical metabolic pathways produce no 
net product but consume energy(69). 
1.3.1.3 Glucagon in diabetes 
Glucagon was first postulated as a potential factor in the pathogenesis of 
T2DM in the “bihormonal hypothesis” by Unger et al in the 1970’s(70). 
This theory suggests that the cause of T2DM is not only a reduction in 
insulin but also dysfunctional secretion of glucagon. In support of this, 
patients with T2DM have higher baseline and postprandial glucagon 
levels compared to those with normal glucose tolerance(71). This is in 
contrast to the suppressed glucagon response to a carbohydrate meal in 
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subjects with normal glucose tolerance. Further evidence to support the 
role of glucagon in the pathology of diabetes is a study in which a 
glucagon receptor antibody administered to type 1 diabetic (T1DM) mice 
resulted in improvements in HbA1c.(72) In contrast to these findings, 
RYGB with normal glucose tolerance  have elevated postprandial 
glucagon(73,74). In addition chronic administration of glucagon to 
Wistar rats resulted in reduced plasma glucose as opposed to any 
detrimental effect on glucose homeostasis(55). 
1.3.2 Glucagon-like peptide-1 (GLP-1)  
1.3.2.1 Structure and processing of GLP-1 
GLP-1, like glucagon and oxyntomodulin (OXM), is produced by post-
translational processing of pro-glucagon. The products of this process are 
tissue specific and dependent on the prevalence of prohormone 
convertases. Whilst GLP-1 and OXM are products of tissues that contain 
prohormone convertases 1/3, the presence of prohormone convertase 2 in 
pancreatic α cell yields glucagon (53,75). Total or full-length GLP-1 1-37 
has limited biological activity. However, the removal of six amino acids 
from the N-terminal results in the two bioactive forms; GLP-1 7-37 and 
GLP-1 7-36  amide of which the latter is more predominant.  
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Both bioactive forms have a short half-life of 1-2 minutes due to the 
activity of the ubiquitous enzyme Dipeptidyl-Peptidase 4 (DPP-4) which 
cleaves two amino acids to produce the biologically inactive GLP-1 9-36 
amide(76).  Active GLP-1 is also a substrate for the peptidase neprilysin 
(neutral endopeptidase 24.11)(77). In vitro studies have identified six 
cleavage sites in the central and C-terminal regions of the GLP-1 peptide 
that neprilysin acts on(78). These are  
1. Glu27-Phe 28 
2. Trp31-Leu32 
3. Asp15-Val16 
4. Ser18-Tyr19 
5. Tyr19-Leu20 
6.  Phe28-Ile29. 
 
1.3.2.2 Distribution and secretion of GLP-1 
GLP-1 is found in both the intestine and the CNS(51,79). Within the 
intestine, GLP-1 is secreted from the enteroendocrine L cell. L cells 
secrete multiple hormones including OXM and PYY(80,81). The peptide 
products of the L cell vary depending on their position within the 
gastrointestinal tract. The highest concentration of L cells secreting GLP-
1 are found within the ileum(82).  
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 GLP-1 expressing neurons are particularly prevalent in the caudal portion 
of the NTS(79). Ascending axons from GLP-1 producing neurons spread 
to the forebrain and brainstem regions associated with metabolic and 
autonomic control in the mouse, including the ARC, PVN, rostral 
ventrolateral medulla and DMN(83). These projections correlate well 
with the pattern of GLP-1R expression throughout the rat brain(84). 
 
1.3.2.3 Regulation of GLP-1 release in the intestine  
Intestinal GLP-1 secretion is linked to meal ingestion with release lowest 
in the fasting phase and highest in the postprandial phase(85). 
Carbohydrates, fats and proteins all stimulate GLP-1 release(86,87). 
There are multiple mechanisms by which L cell secretion of GLP-1 is 
linked to nutrient sensing and involves neural, paracrine and endocrine 
mechanisms.  
 
Neural and hormonal mechanisms are particularly relevant to the acute 
phase of GLP-1 secretion (rapid rise in the first 30-60 minutes of eating). 
The vagal nerve can stimulate GLP-1 secretion as demonstrated in rat 
studies in which stimulation of the sub diaphragmatic vagus nerve results 
in an increase in plasma concentrations of GLP-1(88). Glucose dependent 
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insuliontrophic peptide (GIP) released from L cells on the proximal small 
bowel can also stimulate GLP-1 secretion (88).  
 
The chronic phase of release is mediated by direct sensing of nutrients in 
the enteral lumen. Glucose sensing by enteroendocrine cells involves a 
number of mechanisms. A critical component of glucose sensing in the 
gut is Na+-coupled glucose uptake by sodium glucose transport protein 1 
(SGLT1), which generates small currents that trigger depolarization and 
voltage-gated Ca2+ entry(89). Glucose metabolism, involving glucokinase 
and the closure of ATP-sensitive (KATP) channels(90), and 
basolateral/plasma glucose concentration may also play a role in glucose- 
stimulated gut hormone release.  
1.3.2.4 Receptors and signalling cascades  
The GLP-1 receptor (GLP-1R), is a seven trans-membrane domain, G-
protein-coupled receptor (GPCR) in the secretin-like class B family(91). 
Expression of GLP-1R is distributed in pancreatic islets, lung, central and 
peripheral nervous system , stomach, kidney and heart (91,92).  
 
GLP-1R binding by an agonist results in activation of two separate 
secondary messenger pathways. The first involves cAMP production via 
the Gs G-protein(93). An alternative pathway for stimulated cAMP 
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involves recruitment of the scaffold protein ß-arrestin and downstream 
activation of ERK, CREB, and increased IRS-2 expression (94).  
1.3.2.5 Biological actions of GLP-1  
1.3.3.5.1 Glucose metabolism 
GLP-1 has a number of actions that affect carbohydrate tolerance. Firstly 
it functions as an incretin hormone, (it is a hormone that increases 
circulating insulin levels in response to an oral glucose load relative to an 
intravenous challenge) (95). It stimulates pancreatic ß cell proliferation 
and differentiation(96), insulin gene expression(97) and insulin secretion 
and is capable of normalising the blunted insulin responses to glucose 
seen in type 2 diabetic patients(98). In addition to its insulintropic effect, 
GLP-1 also suppresses glucagon release in a glucose-dependent fashion 
from α cells, likely via somatostatinergic mechanisms (99,100). In 
addition, the effects of GLP-1 on gastric emptying(101) and food 
intake(102) also contribute to a net reduction in postprandial glucose 
levels. 
  
1.3.3.5.2 Food Intake  
GLP-1 has been shown to inhibit food intake in both rats as well as 
man(103-105).In rats this anorectic effect has been observed with both 
central and peripheral administration of GLP-1(103,104). GLP-1’s 
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anorectic effect is likely due to a combination of peripheral and central 
action. Delayed gastric emptying subsequent to GLP-1 administration is 
likely to contribute to its anorectic effect(106), although it has been 
reported that this effect may be temporary due to tachyphylaxis(107). The 
central action of GLP-1 is demonstrated by the activation of multiple 
areas within the brain including the PVN, SON of the hypothalamus, 
NTS and AP(108-110). However, the mechanism is likely to be 
independent of activation of the MC4R as studies using a MC4R 
antagonist (AgRP(83-132) did not attenuate GLP-1’s anorectic 
effect(111).  
 
Evidence of a vagus mediated anorectic effect of GLP-1 is demonstrated 
by the presence of the GLP-1R gene expression in the vagal nodose 
ganglion(112) and that a truncal vagotomy yields a reduction in GLP-1’s 
effect on food intake(110). 
1.3.3.5.3 Cardiovascular actions  
Beyond GLP-1 actions on glucose metabolism and weight loss it also 
noted to have an important impact on the cardiovascular system(113). 
These effects include an increase in heart rate(114), a lowering of blood 
pressure(115) and an improvement in vascular endothelial dysfunction 
which is a risk factor for atherosclerosis(116). The mechanism underlying 
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the rise in heart rate and the clinical significance of this remains unknown 
The benefits on blood pressure may be due to increased natriuresis(117) 
or vasodilation(118). These effects (except the increase in heart rate) 
suggest a cardio-protective effect and this has been observed in clinical 
trials(119).  
 
1.3.2.6 GLP-1 physiology in T2DM 
The potential of GLP-1 as a treatment for T2DM is based on the 
following observations on GLP-1 and the pathology of T2DM. Firstly, 
patients with T2DM have a reduction in postprandial GLP-1 which may 
contribute the attenuation in stimulated insulin secretion(120). Secondly, 
patients with T2DM continue to be sensitive to the incretin effects of 
exogenous GLP-1, unlike GIP, where the incretin effect is significantly 
blunted in these patients Lastly, infusion of GLP-1 rapidly normalises 
hyperglycaemia in patients with T2DM(99,117) 
 
This has lead to the rapid development to a number of GLP-1 analogues 
that have been designed to be resistant to DPP-4 and so prolong their half 
life relative to the native peptide. The first of these is exenatide (exendin-
4, Bristol-Meyers Squibb). Exenatide was originally isolated from the 
saliva of the Gila monster lizard. It shares a 53% homology with human 
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GLP-1 and is given as a subcutaneous (SC) injection twice a day.  An 
improvement in HbA1c by 0.8-1.11% and reduction in weight between 
1.6 to 2.8 kg has been reported with twice daily exenatide (121). The 
most common side effect with exenatide is that of nausea and vomiting, 
both of which attenuate with time and are reduced by a slow titration up 
in dose.  
 
However, dissatisfaction with a therapy that requires self-injection twice 
a day has resulted in the pharmaceutical development of GLP-1 
treatments moving forward in two separate pathways.  
 
As an alternative to injectable GLP-1 analogues is the development of 
oral DPP4 inhibitors that act to increase endogenous GLP-1 levels. 
Examples of these include sitagliptin, vidagliptin and satagliptin. 
Sitagliptin is taken once a day and causes a reduction in HbA1c of 
0.7%(122). However, one drawback of the gliptins is that they are weight 
neutral.  
 
The alternative approach has been to attempt to improve patient 
satisfaction by prolonging the half-life of GLP-1 agonists.  The first of 
these was liraglutide (Novo Nordisk).  This analogue is 97% identical to 
native GLP-1, but contains an amino acid substitution (K34R) to allow a 
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palmitate fatty acid group to be linked via a γ– glutamic acid spacer. The 
fatty acid group binds to albumin, increasing the half-life of liraglutide to 
13 hours. In contrast to the DPP4 inhibitors, liraglutide can generate 
weight loss and is now licensed for the management of obesity by the 
FDA. Phase 3 trials of liraglutide given SC daily have shown a weight 
loss of 5.6% subtracted from placebo(123). 
 
 
 
 
 
 
Figure 1.2 Proglucagon cleavage. Proglucagon expression is centred in 
the pancreas, GI tract and brain. Glucagon is the primary secretory 
product in the pancreas, whereas GLP-1 and OXM production takes place 
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mainly in the GI tract and brain. Abbreviations: GRPP, glicentin-related 
polypeptide; IP, intervening peptide; GI, gastrointestinal; GLP, glucagon-
like peptide; MPGF, major pro-glucagon fragment. Location in the pro-
glucagon peptide sequence is indicated by numbers. Adapted from Field 
et al  (124). 
 
1.3.3 OXM  
1.3.3.1 OXM- discovery and structure 
OXM derives its name for its ability to modulate gastric acid secretion 
from gastric oxyntic glands(125). It was initially identified in 1968 from 
gastric extracts that cross-reacted with glucagon in 
radioimmunoassays(126). However, it was in 1981 when the structure of 
OXM was elucidated. It is a 37 amino acid peptide that contains the 
entire 29 amino acid sequence of glucagon combined with 8 amino acid 
carboxy-terminal extension. It is a product of post-translational of the 
preproglucagon precursor. Production of OXM is tissue specific and 
dependent on the presence of prohormone convertase 1/3(53,75).  OXM 
has a similar distribution to GLP-1; ileum, jejunum, colon as well as 
neurons in the NTS and hindbrain. 
1.3.3.2 Secretion of OXM 
OXM is released from the intestinal L cells 5–10 minutes after meal 
ingestion, in amounts proportional to the calorie intake (127,128). 
Circulating levels of OXM peak at around 30 min after ingestion(129). 
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OXM demonstrates a diurnal variation, independent of food intake, with 
levels highest in the evening and lowest in the early morning(128). 
 
1.3.3.3 OXM signalling 
At present, no separate OXM receptor has been identified. However, 
OXM binds to and is an equipotent agonist of both the GLP-1 and 
glucagon receptors, although it affinity to those receptors is reduced 
relative to their cognates (130). 
 
1.3.3.3.1 OXM and GLP-1 receptor. 
Evidence that anorectic actions of OXM are mediated via the GLP-1 
receptor is based on the following two observations. Firstly, the weight 
loss seen in wild type mice injected with OXM is abolished in GLP-1R -
/- mice(131). Secondly, the administration of exendin9-39  (a GLP-1 
antagonist) into the cerebral ventricles of mice inhibits the anorectic 
actions of both GLP-1 and OXM(131). 
 
There is emerging data that OXM binding to the GLP-1R may have a 
differing biological actions than GLP-1. This is based on contrasting 
secondary messenger recruitment. Specifically OXM is a functional 
antagonist in β-arrestin 2 activation. This distinction in signalling may 
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also account for the observed difference in hypothalamic pathway 
activation between OXM and GLP-1(132). 
 
1.3.3.3.2 OXM and the glucagon receptor 
Whereas the anorectic actions of OXM were abolished in GLP-1R 
knockout mice, there were other effects that persisted such as increased 
heart rate, energy expenditure and glycogenolysis(131). It has been 
postulated that these actions are mediated via the glucagon receptor. 
Evidence to support this comes from experiments that have utilized an 
OXM analogue that has been modified via a mutation of gln to glu at 
position 3. The resultant analogue known as OXMQ3E, has diminished 
binding of the glucagon receptor(133). Studies comparing OXM to 
OXMQ3E have demonstrated the former induces greater glycogenolysis, 
weight loss, and reduction in lipid levels(134). This suggests that 
activation of the glucagon receptor is relevant to the weight loss observed 
with OXM. 
1.3.3.4 Biological actions of OXM 
1.3.3.4.1 Weight loss 
OXM causes weight loss in humans and rodents(131,135-138). 
Overweight and obese subjects receiving SC administration three times 
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daily of OXM (400 nmol pre-prandially) over a 4-week period resulted in 
an average weight loss of 2.3 kg(139).  
 
In animal studies, OXM was shown to lower body weight as well as 
increase core temperature compared to a pair-fed group. This implies that 
some of the weight loss produced by OXM is mediated via an increase in 
energy expenditure(136,138). This effect was later confirmed by indirect 
calorimetry(131).  
 
In humans, the there is an acute anorectic effect of exogenous OXM 
which is sustained with chronic administration(135,139). Furthermore, in 
overweight and obese volunteers, SC self- administered OXM was 
effective at reducing weight due to a combination of reduced food intake 
and increased energy expenditure(137).  
1.3.3.4.2 Glucose metabolism 
OXM improves glucose metabolism in both mice and men(140,141). 
Similar to GLP-1,  the mechanism for this could be due to an incretin 
effect and a reduction in gastric emptying(142,143). 
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1.3.4 Peptide YY (PYY)  
PYY is a peptide hormone that was first isolated from porcine small 
intestine in 1980(144). Its name reflects a high proportion of tyrosine 
residues, specifically one at both the N- and C-terminals.  
1.3.4.1 Structure of PYY  
PYY is a 36 amino acid peptide hormone. It is a member of the PP fold 
family that includes PP and NPY which all share a common hairpin-like 
U-shaped fold tertiary structure.  
1.3.4.2 Processing of PYY 
The precursor of PPY is pre-proPYY which has an additional signal 
peptide, and a C-terminal extension peptide that are joined to PYY (145). 
Processing of pre-proPYY involves cleavage of the signal peptide, 
amidation of the C-terminal tyrosine, which is necessary for biological 
activity, and proteolytic cleavage by a prohormone convertase to give 
PYY1-36, the 36 amino acid form of the peptide, which is secreted. The 
secreted PYY1-36 is a target for DPP-4 which cleaves the amino terminal 
tyrosine proline dipeptide to generate PYY3-36, which is both the 
biological active  and predominant circulating form of PYY(146,147).  
1.3.4.3 Distribution and secretion of PYY  
PYY is secreted from the entero-endocrine L cells of the gastrointestinal 
tract, Whilst L cells are distributed throughout the small and large bowel, 
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PYY expression progressively increases from the small bowel to its 
highest concentration in the rectum (148).PYY is also produced in the 
gigantocellular reticular nucleus of the hindbrain and the 
pancreas.(149,150) 
 
Plasma levels of PYY peak at 1-2 hours following a meal and remain 
elevated for up to 6 hours(148).Calorie and macronutrient content are 
independent factors in determining the amount of PYY secreted. The 
peak postprandial levels of PYY are proportionate to the calorific content 
of food ingested(151). It remains clear which macronutrient is the most 
potent stimulator of PYY secretion. Studies investigating different 
isocaloric meals of different macronutrient content have demonstrated 
that protein is the most potent macronutrient stimulus for PYY release, 
followed by fat and then carbohydrate(152). However, when an 
intraduodenal route was used, fat was more potent than protein in 
promoting PPY release(153). 
 
Neural or hormonal regulation may be more relevant to PYY release, as 
studies in humans have shown that circulating PPY starts to rise 15 
minutes postprandially, before direct stimulation of the L cell is likely to 
occur. (154).  
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1.3.4.4 PYY Receptors  
PYY binds to the Y family of G protein coupled receptors. In mammals, 
five receptor subtypes have been cloned, namely Y1, Y2, Y4, Y5 and 
Y6(155). In humans, PYY1-36 binds to all receptors in the Y family (Y1, 
Y2, Y4 and Y5). PYY3-36, the predominant circulating form of PYY, is 
more selective for the Y2 and Y5 receptors, and has a lesser affinity for 
Y1 and Y4 receptors(156)  
1.3.4.5 Biological Actions of PYY  
1.3.4.5.1 Inhibition of Appetite and Food Intake  
PYY 3-36 has an inhibitory effect on food intake in rats when injected 
peripherally or centrally into the ARC(157). This anorexic effect is lost 
when PYY3-36 is given centrally to Y2 receptor null mice suggesting 
that the satiating action of PYY3-36 is mediated via Y2(157).The effects 
of PYY3-36 on food intake are reduced in both Y1 receptor and Y5 
receptor null mice, implying that Y1 and Y5 receptors also play a part in 
central control of appetite (158). Nevertheless,  the predominant receptor 
mediating PYY3-36 anorectic action is likely to be the Y2 receptor(159). 
This is supported by the fact that a selective Y2 receptor antagonist, when 
injected into the ARC, blocks the anorexigenic effect of peripherally 
administered PYY3-36(160). 
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Further evidence demonstrating the physiological role of PYY in appetite 
regulation is demonstrated by observations regarding PYY- null mice. 
They are known to be hyperphagic(152) and MRI imaging demonstrates 
that they have greater levels of fat than controls(152).Treatment with 
PYY3-36 revers their obesity phenotype(152). 
 
The anorexic effect of PYY3-36 is also applicable to humans as observed 
when an acute intravenous infusion (dosed to replicate postprandial 
levels) resulted in a reduction in food intake in both non-obese and obese 
individuals. These healthy subjects also had a significant reduction in the 
subjective feeling of hunger as assessed by visual analogue scores 
(VAS)(157).  
 
The mechanism of PYY’s anorectic action is multifactorial. There is a 
contribution of central inhibition of appetite, specifically an inhibition of 
the orexigenic NPY/AgRP neurons within the hypothalamus. PYY3-36 
when administered directly into the ARC, acts via pre synaptic Y2 
receptors to inhibit NPY/AgRP(157). Exposure to PYY3-36 results in 
suppression of Npy mRNA(157). Furthermore, electrophysiology studies 
showed that PYY3-36 activates anorexigenic POMC/CART 
neurons(157). The proposed mechanism for this was a reduction in the 
GABA-mediated tonic inhibition of the anorexigenic POMC/CART 
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neurons by the NPY/AgRP neurons. However, in contrast to this 
observation, PYY3-36 administration produces weight loss in the POMC 
knock-out mouse(161). Furthermore, there is now evidence that PYY 3-
36 inhibits POMC neurons via a post synaptic Y2 receptor(162).  
 
The presence of Y2 receptors on the vagal nerve implicates its 
involvement in the anorectic action of PYY3-36(163). Vagel affernts 
Furthermore vagotomy abolished the anorectic effects of IV PYY3-
36(163).  
 
However, peripherally administered PYY3-36 is still able to activate 
POMC/CART neurons in the ARC even with vagotomy(163).Therefore, 
PYY3-36 can suppress food intake via two sites of action, the 
hypothalamus and the vagus nerve. A further indirect mode of inhibition 
of appetite is that in humans, administration of PYY3-36 resulted in a 
decrease in the orexigenic hormone ghrelin(164).  
 
1.3.4.5.2 Effects on Glucose Metabolism  
Two separate observations support a role for PYY in glucose 
homeostasis. Firstly, both pyy and Y1 receptor knock out mice exhibit 
hyperinsulinaemia(165,166). Secondly, pancreatic islets cells express 
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PYY, specifically α and δ  but not β cells(167). This suggests a potential 
paracrine role.  
 
PYY1-36 and PYY 3-36 have contrasting effects on glucose homoestasis. 
Whilst the administration of PYY1-36 to isolated islet cells results in a 
decrease in glucose dependent insulin secretion(168), injections of 
PYY3-36 or Y2 receptor agonist to rodents improves glucose 
homeostasis(169-171). 
 
The postulated paracrine effect of PYY is likely to be specific to PYY1-
36 as mRNA encoding Y1 and Y4 receptors has been detected in both 
human and mouse islets(166,172). Y2 receptor mRNA in islets cell has 
not been detected suggesting any effect of PYY3-36 on insulin secretion 
is indirect(173).  
 
Alternative mechanisms by which PYY3-36 may affect glucose 
homeostasis include an increase in either GLP-1 secretion or insulin 
sensitivity(169,174). Evidence supporting a role for PYY3-36 stimulation 
of GLP-1 comes from mouse studies by Chandarana et al that 
demonstrated an increase in the concentration of GLP-1 within the 
hepatic portal vein following injection of PYY3-36, with no increase 
observed in the systemic circulation. Chandarana et al have also 
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demonstrated that the improvement in glucose homeostasis observed after 
PYY3-36 injection is diminished in the presence of the GLP-1 antagonist, 
Exendin9-39(174). An improvement in insulin sensitivity has been 
demonstrated by van den Hoek et al using euglycaemic clamp studies 
involving PYY3-36 infusions in mice. However, as this study did not 
measure GLP-1 concentrations during the PYY3-36 infusion, it remains 
unclear whether effect may relate to GLP-1(169). 
 
Whilst the above in vitro and rodent studies support the role of PPY in 
glucose regulation, there are conflicting data obtained from human 
studies. Sloth et al, using a 0.2 pmol/kg/min infusion of PYY3-36 in man 
demonstrated an increase in insulin secretion(175). However, an infusion 
of 0.15 pmol/kg/min of PYY3-36 by Tan et al, in humans during an 
Intravenous Glucose Tolerance Test (IVGTT) demonstrated neither an 
increased insulin sensitivity nor insulin secretion (176). However, the 
contradictory data may reflect the multiple differences in methodologies 
such as different doses of PYY and alternative deliveries of glucose (via 
an oral route by Sloth et al relative to an intravenous route by Tan et al).  
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1.3.5 Evidence that gut hormones are important in weight 
loss after RYGB 
 
Whilst the mechanism behind the rapid improvement in diabetes and 
sustained weight loss after RYGB remains unclear, changes in levels of 
gut hormones have been postulated as being responsible. Post RYGB 
subjects when given a meal or glucose challenge have postprandial levels 
of gut hormones that are significantly higher than weight matched 
controls given the same stimulus (177-179). These increased postprandial 
levels of GLP-1 and PYY are seen early after the operation and this 
change appears durable (180). Interestingly, the meal stimulated rise in 
PYY increments persists over the course of a year but this does not occur 
with GLP-1 (181,182). There is currently no data on how long circulating 
OXM remains elevated following surgery.  
 
Elevated postprandial levels of glucagon after RYGB are increasingly 
being recognised(73,74,183). There is discordance in the literature over 
how long this increase persists, with some studies reporting elevated 
levels for two weeks to three months before returning to pre-surgery 
levels at one year(73,74) whilst other demonstrating a persistently raised 
postprandial glucagon level at one year (184). 
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Elevated glucagon following bariatric surgery is an interesting 
observation. Whilst its role in increasing energy expenditure and reducing 
appetite would correlate with the weight loss observed after RYGB, the 
expected hyperglycaemia induced by glucagon is inconsistent with 
amelioration in diabetes that occurs post-operatively. It is possible that 
any glucagon-induced hyperglycaemia in counterbalanced by the elevated 
post-prandial incretins.  
 
Although these data suggest that the increased secretion of gut hormones 
are important in the observed weight loss after RYGB, there is a paucity 
of evidence that directly links the two phenomena. There is some 
evidence from rodent models. Chandarana et al. created a mouse model 
of RYGB that led to greater weight loss than sham operated mice (185). 
This difference in weight loss was not present in Pyy knockout mice, 
suggesting that PYY secretion was a key factor in mediating the weight 
loss, at least in this particular surgical model of RYGB. 
   
1.4 Postprandial Hypoglycaemia- a metabolic 
complication of RYGB surgery 
The RYGB operation is considered a relatively safe surgical procedure. It 
has a 30-day mortality of 1 in 200 giving it a safety profile comparable to 
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other elective procedures such as a laparoscopic cholecystectomy(39). 
However, as the rate of RYGB operations increases in response to the 
rapid rise in obesity, previously rare metabolic complications are 
becoming more common. An example of this is postprandial 
hypoglycaemia (PPH). PPH in the context of RYGB was first reported in 
a case series of 6 patients in 2005. Since this first recognition of 
hyperinsulinemic hypoglycaemia after RYGB, there has been a dramatic 
rise in cases reports as well as studies aimed at exploring the pathology 
and treatment of this condition. 
1.4.1 Incidence of PPH 
The reported incidence of PPH post RYGB is reported as 0.1%(186). 
However, this study has several limitations. It was a retrospective review 
of a Swedish database of surgical patients. As such it was dependent on 
self-reporting of a condition that remains under recognised by both 
patients and physicians. 
1.4.2 Pathogenesis of PPH 
Data regarding this is conflicting. In the first case series of PPH, Service 
et al, went on to perform partial pancreatectomies on his cohort of six 
patients(187). A comparison analysis between the histopathology of 
pancreata between the PPH patient and a control group revealed islet cell 
hyperplasia. It was subsequently postulated that RYGB may result in a 
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form of nesidioblastosis. However, when another group reanalysed the 
pancreata from this cohort and compared the histology to a BMI matched 
control set, there  was no significant difference in the size of the β cell, 
implying that the features observed in the pancreata were secondary to 
obesity as opposed to RYGB(188). It should also be noted that of the six 
patients in the original cohort who were operated on, 50% had recurrence 
of symptoms(187). 
Since then, there has been speculation within the literature as to the 
whether the altered hormonal milieu that occurs after RYGB may account 
for the hyperinsulineamic hypoglycaemia. Specifically, it has been 
postulated that the elevated levels of GLP-1, an  insulinotropic hormone, 
could be the causative factor. Studies investigating this hypothesis have 
produced conflicting data. Goldfine et al have demonstrated elevated 
fasting and post prandial levels of GLP-1 in a group of 12 patients with 
PPH in comparison to 12 asymptomatic RYGB patients(189). 
Furthermore, Salehi et al infused exendin 9-39 (a GLP-1 antagonist) in 
patients with PPH and demonstrated amelioration in biochemical 
hypoglycaemia. However, in contrast to these results, patients with PPH 
who undergo reversal of their operation have a reduction in their GLP-1 
levels but do not see an improvement in their symptoms(190). Also 
conflicting with this is a case series of patients with PPH that have 
successfully been treated with liraglutide, a GLP-1 analogue(191).  
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1.5 Aim of Studies 
This thesis will describe investigation of post RYGB physiology, 
focusing on glucagon, GLP-1, OXM and PYY. Specifically, these studies 
have examined:  
• The effects of co-infusion of glucagon and GLP-1 on carbohydrate 
tolerance after a standard mixed meal test. 
• The effects of chronic co-infusion of GLP-1, OXM and PYY on 
food intake   
• The hormonal milieu in postprandial hypoglycaemia  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1.6 Hypotheses  
The presented studies have addressed the following specific hypotheses.  
1.Co-infusion with GLP-1 and glucagon will attenuate the 
hyperglycaemia observed when glucagon is administered alone 
2. Co-infusion of GLP-1, OXM and PYY can reduce food intake 
3. GLP-1 is elevated patients with postprandial hypoglycaemia. 
  
 59 
Chapter 2:       
 The acute effects of co-infusion of 
glucagon and GLP-1 on 
carbohydrate tolerance in humans 
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2.1 Introduction 
Currently, the most effective treatment for obesity is RYGB surgery,  
resulting in a mean 27% sustained reduction in pre-surgical weight(192). 
In addition, there is a rapid improvement in glycaemic control that occurs 
shortly after surgery suggesting mechanisms independent of weight 
loss(193,194). The mechanism by which RYGB achieves weight loss and 
diabetes remission remains unclear. The  associated postprandial increase 
in a number of gut hormones suggests a potential causative 
mechanism(177). One such gut hormone is GLP-1; a 36 amino acid 
peptide secreted postprandially from enteral L cells in response to 
macronutrients. GLP-1 has multiple actions that could contribute to the 
metabolic benefits observed after RYGB, including a satiating 
effect(102), a delay in gastric emptying(101), an insulinotropic action 
(the so-called incretin effect)(95), and suppression of glucagon secretion 
(195). 
 
These observations have led to the development of GLP-1 receptor 
agonists that are currently used in the treatment of obesity and 
diabetes(196). However, the therapeutic potential of these medications 
has been effected by dose-limiting nausea. As a result, the weight loss 
induced by GLP-1 agonists is modest relative to RYGB surgery(123). 
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Combining GLP-1 with other gut hormones that are elevated after RYGB 
may result in greater weight loss. One potential example of this is the 
combination of GLP-1 with glucagon.   
 
Glucagon is a 29 amino acid peptide secreted from the α cells of the 
pancreas. It stimulates gluconeogenesis and glycogenolysis, which in turn 
increases plasma glucose. Despite promoting hyperglycaemia, glucagon 
has many other actions that make it an attractive anti-obesity therapeutic 
agent, including an increase in satiety, a reduction in food intake, and an 
increase in resting energy expenditure(49,62,197).  
 
The rationale for the development of dual GLP-1/glucagon treatments 
reflects previous studies of another gut hormone, the 37 amino acid 
peptide OXM. Following RYGB, plasma OXM concentrations 
increase(179). Administration of OXM  to healthy overweight and obese 
volunteers, causes a reduction in  appetite, weight and an increase in 
energy expenditure(135,139). Interestingly, OXM has no known specific 
receptor but is a weak agonist of both the GLP-1 and glucagon 
receptors(130). Furthermore, OXM has a longer half life than either GLP-
1 or glucagon. Hence, it has been postulated that the benefits of OXM are 
mediated via dual agonism of GLP-1 and glucagon receptors.  
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This hypothesis has been supported by a series of studies. Two separate 
groups have tested dual GLP-1/glucagon agonists and demonstrated 
greater weight loss in rodents than achievable with GLP-1 agonists 
alone(198,199). An earlier study from this department has co-infused 
sub-anorectic doses of glucagon and GLP-1 in rodents, demonstrating 
greater appetite suppression than with administration of either individual 
peptide(200), and this observation was replicated more recently in human 
volunteers(201). Furthermore, it has been shown that the addition of 
glucagon to GLP-1 produces a significant increase in energy expenditure 
when compared to saline or GLP-1 alone(49). These data not only 
support the notion that dual agonism of GLP-1 and glucagon receptors 
mediates the effects of OXM, but also highlights its potential as an anti-
obesity treatment. 
 
Historically, glucagon’s deleterious effects on glucose metabolism have 
prevented its development as a treatment for obesity. The addition of 
GLP-1 to glucagon may ameliorate glucagon’s hyperglycaemic 
effect.The observation of attenuation in postprandial glucose levels with 
GLP-1 and glucagon, relative to glucagon alone is consistent with this, 
(201). However, conclusions from this study should be interpreted with 
caution as an ad libitum meal, rather than a standardised meal, was used. 
Hence, the significant reduction in food intake achieved following co-
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infusion of glucagon and GLP-1 relative to glucagon alone might explain 
the reduction in postprandial glucose concentration. 
 
Further support for the attenuation of postprandial hyperglycaemia by 
combining GLP-1 with glucagon comes from observations in patients 
after RYGB. In addition to the established rise in GLP-1, there is a 
parallel exaggerated elevation in plasma glucagon after ingestion of a 
mixed meal, with a doubling in peak postprandial levels relative to 
fasting levels(73,74,183). As RYGB patients have improved 
carbohydrate tolerance, this suggests that either glucagon in this setting 
does not cause an elevation in postprandial glycaemia, or that the 
observed raised GLP-1 levels attenuate any glucagon-induced 
hyperglycaemia. 
 
At present, no study has evaluated the effects of a co-infusion of GLP-1 
and glucagon infusion on carbohydrate tolerance in man. To address this, 
I have studied the effects of infusions of GLP-1 and glucagon, either 
individually or in combination, on glucose tolerance.  
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2.2 Hypothesis and aims 
2.2.1 Hypothesis 
The hyperglycaemic effects of intravenous glucagon can be attenuated by 
the co-administration if intravenous GLP-1 in man. 
2.2.2 Aim 
To investigate the acute effects of co-infusion of glucagon and GLP-1 on 
glucose tolerance in healthy, overweight volunteers. 
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2.3 Materials and Methods 
2.3.1 Peptides 
Glucagon and GLP-17-36 amide were purchased from Novo Nordisk 
(Crawley, UK) and Bachem Ltd (Switzerland) respectively. Glucagon 
was dissolved in the solvent provided by Novo Nordisk (1 ml water for 
injection, lactose monohydrate, hydrochloric acid and sodium hydroxide 
for pH adjustment) whilst GLP-17-36 amide was dissolved in 1 ml sterile 
0.9% saline (Bayer, Haywards Heath, UK). Gelofusine was supplied by 
B. Braun Medical Ltd (Sheffield, UK).  
 
2.3.2 Subjects 
Ten healthy overweight volunteers, 6 men and 4 women, of mean age 
31.9± 10.2 years (range 20 – 49 years), mean weight 81.1±8.0kg (range 
67.4-93.0kg), mean height 1.72±0.07m (range1.63-1.86m), mean BMI 
27.4±2.04kg/m2 (range 25.1-30.4kg/m2) were recruited. Inclusion criteria 
were: age 18 years and over, BMI of  25–35 kg/m2, with stable weight for 
at least three months. Exclusion criteria were: history of any medical, 
psychological or other condition, or use of any medications, including 
over-the-counter products, which, in the opinion of the investigators, 
would either interfere with the study or potentially cause harm to the 
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volunteer, without access at home to a telephone, or any other factor 
likely to interfere with the ability to participate reliably in the study, 
history of hypersensitivity to any of the components of the infusions, 
treatment with an investigational drug within the preceding 2 months or 
who had donated blood during the preceding 3 months or intention to do 
so before the end of the study. Women who were currently pregnant, 
breastfeeding or unable to maintain adequate contraception for the 
duration of the study and for one month afterwards were also excluded. 
 
All subjects were screened and determined to be in normal health (or 
have no significant disease process), by medical history, physical 
examination, 12 lead electrocardiogram and routine biochemistry and 
haematology. Women of child bearing age were advised to avoid 
pregnancy during the study and underwent urine tests to exclude 
pregnancy prior to each study. Any abnormal eating behavior was 
assessed using the Dutch Eating Behaviour Questionnaire (DEBQ) and 
the SCOFF questionnaire(202,203). The study was approved by the 
Hammersmith & Queen Charlotte’s Ethics Committee (reference no. 
10/H0707/80). All subjects gave written informed consent, and the study 
was planned and performed in accordance with the Declaration of 
Helsinki and Good Clinical Practice.  
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2.3.3 Protocol  
Each subject attended for five study visits. The first visit was to 
acclimatise the subject to the clinical environment and to experimental 
procedures. This acclimatisation visit was run in identical fashion to 
subsequent, randomised double-blinded visits, except that the infusion 
always consisted only of vehicle. Data from the acclimatisation visit were 
not included in the analysis. The subsequent four visits followed a 
randomised, double-blind, placebo-controlled crossover design 
comparing four different infusions: (1) Vehicle alone (Gelofusine® – B. 
Braun Medical Ltd, Sheffield, UK); (2) glucagon alone (1.4 
pmol/kg/min); (3) GLP-17-36 amide alone (0.4 pmol/kg/min); (4) 
combination (glucagon + GLP-17-36 amide together (1.4 pmol/kg/min and 
0.4 pmol/kg/min respectively)). A sub-anorectic dose of GLP-1 
previously reported in the literature was used(102,201,204). This dose 
has been previously shown to produce plasma active GLP-1 
concentrations of 15-20 pmol/l, similar to concentrations observed in  
post-prandial RYGB patients(205,206). 
  
With regards to glucagon, in a previous study, nausea was experienced by 
three of the 13 volunteers during infusion with 2.8 pmol/kg/min of 
glucagon(201). Given that the nausea uniformly occurred in the 
postprandial state, the current study protocol incorporated a lower dose of 
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glucagon. Previous studies have used infusions of glucagon at 0.86 
pmol/kg/min to reproduce the non-suppressed plasma glucagon levels 
observed in diabetes patients(207). We administered a dose of 1.4 
pmol/kg/min to simulate the elevated postprandial glucagon levels seen 
following RYGB(208). The randomisation was carried out by an 
independent clinician not otherwise involved in the study.  
 
In order to limit adsorption of peptide to the infusion apparatus 
Gelofusine® was used as the vehicle for all peptide infusions, to dissolve 
the contents of the randomised vials of peptide and to prime all syringes 
and infusion lines(209). Each peptide was drawn up under sterile 
conditions in a separate 50 ml syringe and, to allow the use of two 
different infusion rates, delivered by a separate syringe driver  (Graseby 
3100, SIMS Graseby Ltd, Watford, UK, or Asena GH Mk III, Alaris 
Medical Systems Ltd, Basingstoke, UK). Thus, on a visit when the 
volunteer received only one peptide, the second syringe delivered vehicle 
only, set at the delivery rate calculated for the other hormone. 
  
During the 24-hour period prior to each study visit, participants refrained 
from strenuous exercise and alcohol consumption. They fasted from 10 
p.m. the night before the study, drinking only water. On the morning of 
each study visit, participants attended a dedicated Clinical Investigation 
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Unit at the Hammersmith Hospital. Female participants had a urine ß-
hCG test to exclude pregnancy before the peptide infusion was started. 
Two cannulae were inserted into the participant’s peripheral veins. One 
cannula was used for sampling, and the other one was used to administer 
peptide infusion. The infusion containing the peptide hormone(s) was 
started at 0 minutes. In order to rapidly achieve a steady state, ramping of 
the gut hormone infusions was performed. Ramping was carried out at 
four times the nominal infusion rate for five minutes, then twice the 
nominal infusion rate for a further five minutes, and was then reduced to 
the nominal rate for the remainder of the 220 minute infusion. At 30 
minutes, a meal was served, consisting of liquid (Ensure Plus, 13.8 g of 
protein, 10.8 g of fat, 44.4 g of carbohydrates, 330 kcal, 220 ml, Abbott 
Laboratories, Abbott Park, IL) and solid components (Nutri-Grain bar, 
1.5 g of protein, 3 g of fat, 26 g of carbohydrates, 133 kcal, Kellogg 
Company, UK). Participants were allowed 10 minutes to consume the 
meal. The hormone infusion continued for 220 minutes in total. 
Participants remained in the study room for 60 minutes following 
termination of the infusion, at which point the cannulae were removed. 
The participant was then discharged home.  
 
Blood samples were collected at 0, 30, 40, 50, 60, 70, 80, 90, 100, 115, 
130, 145, 160 , 190, and 200 minutes, into lithium heparin-coated BD 
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Vacutainer tubes (International Scientific Supplies Ltd, Bradford, UK) 
containing 1000 kallikrein inhibitor units (0.1ml) (Trasylol, Bayer 
Scherin Pharma, Berlin, Germany) for gut hormone analysis. In addition, 
blood samples were collected into plain serum Vacutainer tubes 
containing clot activators and fluoride oxalate tubes for insulin and 
glucose assay respectively. The insulin samples were allowed to clot for 
ten minutes at room temperature, after which they were centrifuged and 
separated and stored at -20°C until analysis. All other samples underwent 
immediate centrifugation at 4°C, after which plasma was promptly 
separated and stored at -20°C until analysis.  
 
The pulse and blood pressure of each subject was measured at t=0, 15, 
30, 60, 100, 130, 160, and 220 minutes. Volunteers asked to complete a 
VAS sheet (appendix 1) at the same time points as pulse and blood 
pressure.  
2.3.4 Plasma Hormone and Other Assays  
2.3.4.1 Glucose and insulin 
Plasma glucose and serum insulin samples were analysed in the 
Department of Chemical Pathology, Imperial College Healthcare NHS 
Trust. Plasma glucose was assayed using an Abbott Architect automated 
analyser (Maidenhead, UK), utilizing a hexokinase- glucose-6-phosphate 
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dehydrogenase method. The analytical range was 0.278–44.4 mmol/L, 
with an intra-assay coefficient of variation of 0.65–1.98% and an inter-
assay coefficient of variation of 0.84–0.93%. Serum insulin was 
measured on an Abbott Architect platform using Abbott reagents which 
has a intra-assay coefficient of variation of 10%. 
2.3.4.2 Glucagon 
Glucagon was measured using established in-house radioimmunoassays 
(RIAs)(127). All samples were assayed in duplicate. Glucagon was 
purchased from Bachem Ltd (Switzerland). All other reagents and 
materials were supplied by Sigma (Poole, Dorset, UK). The glucagon 
labels were prepared by Professor M. Ghatei (Professor of Regulatory 
Peptides, Metabolic Medicine, Faculty of Medicine, Imperial College) 
who iodinated the peptide using the iodogen method and was purified by 
reverse-phase HPLC.  
 
Assays were performed in veronal buffer (1l distilled water containing 
10.3g sodium barbitone, 0.3g sodium azide), at pH 8 with 0.3% BSA (and 
0.02% Tween for the GLP-1 assay) (VWR, UK). Standard curves were 
prepared in assay buffer at 0.5 pmol/ml for glucagon, added in duplicate 
at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100 μl. The glucagon 
antibody (RCS5) was raised in rabbits against the C-terminal of glucagon 
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and is therefore specific for pancreatic glucagon. It does not cross react 
with either glicentin or oxyntomodulin. The antibody was used at a 
dilution of 1:50000. Experimental samples of 50 μl, 100 μl glucagon 
antibody solution and 100 μl of glucagon label solution were used and all 
tubes were buffered to a total volume of 700 μl with assay buffer. The 
assays were incubated for 96 hours at 4oC. Free peptide was separated 
from bound using charcoal adsorption. To each tube, 4 mg of charcoal, 
suspended in 0.06 M phosphate buffer with gelatine was added 
immediately prior to centrifugation. The samples were then centrifuged at 
1500 rpm, 4oC, for 20 minutes. Bound and free label were separated and 
both the pellet and supernatant counted for 180 seconds in a γ-counter 
(model NE1600, Thermo Electron Corporation). Plasma glucagon 
concentrations in the samples were calculated using a non-linear plot 
(RIA Software, Thermo Electron Corporation) and results calculated in 
terms of the standard.  
2.3.4.3 Active GLP-1 
Active GLP-1 immunoreactivity was measured using a commercially 
available ELISA kit (Millipore Corporation, MA, USA), with the 
following specificities: GLP-17-36amide 100%, GLP-17-37 72%, GLP-
11-36 OR GLP-11-37 <2%.  
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2.3.4.4 Measure of β cell sensitivity and function 
The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) 
which is a measure of insulin resistance in the fasting state (210)was 
measured using the HOMA-IR2 calculator by the Oxford Diabetes Trial 
Unit(211). 
 
The insulinogenic index is a measure of β cell function and is calculated 
as the ratio of change in insulin from fasting to 30 minutes post meal to  
the change in glucose from fasting to 30 minutes post meal(212). 
 
2.3.5 Statistical Analysis 
All data are expressed as mean ± SEM unless specified. Two-way 
repeated measures ANOVA with Bonferroni post hoc test was used to 
compare differences in glucose, insulin, pulse, blood pressure and VAS 
scores at specific time points. One-way ANOVA with Tukey post hoc 
test was used to compare differences between AUC insulin and glucose. 
Statistical significance was defined as P<0.05. 
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2.4 Results 
2.4.1 Gut hormone assays 
Mean plasma concentration of active GLP-1 30 minutes before the 
infusion was 6.63±0.13 pmol/l. In the experimental groups receiving 
GLP-1 alone or GLP-1 combined with glucagon, the mean concentration 
rose to 11.57±0.51 pmol/l. There was no significant difference in the 
concentration of active GLP-1 between those that received GLP-1 alone 
or in combination with glucagon (Figure 2.1A). Mean plasma 
concentration of glucagon 30 minutes prior to infusion was 18.90±2.22 
pmol/l, rising to 70.97±5.51 pmol/l at 30 minutes in those receiving 
glucagon, as a single infusion or in combination with GLP-1 (Figure 
2.1B). 
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Figure 2.1 Plama active GLP-1 (A) and glucagon (B) concentrations 
after hormone infusion. Data are given as mean ± SEM. Duration of 
infusion denoted by labelled grey hashed bar. A mixed meal was given at 
T=30 minutes (shown by arrow). N = 10 for each infusion. 
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2.4.2 Glucose and Insulin results 
The effects of vehicle, glucagon, GLP-1 or GLP-1/glucagon in 
combination on plasma glucose and serum insulin are shown in Figure 
2.2. Prior to infusion, mean plasma glucose was 5.12±0.08 mmol/l with 
no significant difference between groups. In the vehicle group, mean 
plasma glucose was constant for the first 30 minutes, but then rose in 
response to consuming the mixed meal to 6.12±0.45 mmol/l at 80 
minutes. Mean plasma glucose then returned to a baseline level at 160 
minutes.  In all infusion groups, plasma glucose concentration returned to 
baseline at this time point.  
 
In those receiving a glucagon infusion, mean pre-prandial plasma glucose 
rose to 6.13±0.30 mmol/l after 30 minutes, which was significantly 
different to the vehicle group (mean plasma glucose: 5.04±0.11 [vehicle] 
vs. 6.13±0.30mmol/l [glucagon], P<0.01). Plasma glucose peaked at 
6.56±0.22 mmol/l at 30 minutes after meal commencement (T=60 
minutes), before dropping to baseline at T=160 minutes. AUC glucose 
T=30-160 was unchanged relative to vehicle (Figure 2.3A). Administration 
of GLP-1 alone significantly decreased mean plasma glucose compared 
to vehicle (mean plasma glucoseT=30: 5.14±0.10 [GLP-1] vs 4.44±0.10 
mmol/l [vehicle P<0.001). Glucose concentrations fluctuated during the 
GLP-1 infusion but never exceeded pre-infusion fasting values. Mean 
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AUC glucose T=30-160 in the GLP-1 group was significantly reduced 
compared to glucagon (Mean AUC glucose T=30-160 615.3±42.3
 [GLP-1] vs 
764.8±17.3  mmol·min/l [glucagon] P<0.05). The combination of GLP-1 
and glucagon significantly attenuated the increase in plasma glucose 
observed by glucagon alone (Mean AUC glucose T=30-160  643.9±32.6
 
[combination] vs 764.8±17.3 mmol·min/l [glucagon] P<0.05).  
 
Following consumption of the mixed meal, serum insulin rose in all 
infusion groups peaking 50 minutes later. Relative to vehicle, the AUC 
insulin T=30-160 was significantly lower in those receiving GLP-1, but there 
was no difference when compared to glucagon alone or co-infusion of 
glucagon and GLP-1. Infusion of glucagon alone produced the highest 
AUC insulin T=30-160. However, the AUC insulin T=30-160  was significantly 
lowered by the addition of  GLP-1 to glucagon compared to 
administration of glucagon alone (AUC insulin T=30-160  73606±12484 
[glucagon] vs 42841±7457 pmol·min/L [combination] P<0.01)(Figure 
2.3B). 
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Figure 2.2 Effects of glucagon, GLP-1 and combination on glucose 
(A) and insulin (B) concentrations. Data are given as mean ± SEM.  
Duration of infusion denoted by labelled gray and hashed bar. 10 
volunteers received each infusion. Significant differences are: 
*Glucagon vs Vehicle P<0.05, GLP-1 vs Glucagon P<0.05, Combination 
vs GLP-1 P<0.05. 
†GLP-1 vs Vehicle P<0.05, combination vs vehicle P<0.05, GLP-1 vs 
Glucagon P<0.05, Combination vs Glucagon P<0.05. 
‡GLP-1 vs Glucagon P<0.05. 
#GLP-1 vs Vehicle P<0.05, GLP-1 vs Glucagon P<0.05, Combination vs 
Glucagon P<0.05. 
**GLP-1 vs Vehicle P<0.05, GLP-1 vs Glucagon P<0.05. 
%GLP-1 vs Vehicle P<0.05, Combination vs Vehicle P<0.05 
$ GLP-1 vs Glucagon P<0.05, Combination vs Glucagon P<0.05 
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Figure 2.3 Effects of glucagon, GLP-1 and combined combination on  
mean AUC glucose (A) and mean AUC insulin (B) during infusion. 
Data are mean AUC ± SEM shown. 10 volunteers received each infusion. 
Significantly different mean AUC values are indicated as follows * 
P<0.05, **P<0.01 ***P<0.001. 
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2.4.3 Measures of insulin sensitivity and insulin secretion 
The effects of each hormone infusion on insulin resistance and secretion 
are shown in Table 21.  As expected, baseline hepatic insulin resistance 
(as measured by HOMA-IR) prior to infusion was similar between the 
groups. There was no significant increase in the insulinogenic index 
comparing all four infusion groups. 
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Table 2.1 Measures of glucose homeostasis during a mixed meal test following infusion of GLP-1, glucagon or a combination of both  
 Vehicle Glucagon GLP-1 Combination Significant differences between groups 
Fasting glucose (mmol/L) 5.19±0.25 5.02±0.15 5.14±0.10 5.14±0.17  
Fasting glucose after 30 
minutes infusion 
(mmol/L) 
5.04±0.11 6.13±0.30 4.44±0.09 5.60±0.21 Glucagon>Vehicle  P<0.001 
Glucagon>GLP-1  P<0.0001 
Glucagon + GLP-1>GLP-1 P<0.0001 
Peak insulin 
(pmol/l) 
749.9±103.3 936.2±132.7 426.2±75.1 666.1±140.9 Glucagon>GLP-1 P<0.05 
Mean time to peak insulin 
(mins) 
82.5±7.7 82.5±7.4 125.0±11.6 105.5±17.6  
HOMA-IR (t=0) 
(mmol·uIU/L2) 
1.95±0.66 1.22±0.24 1.47±0.30 1.41±0.34  
AUCglucose30-160 
(mmol·min/l) 
733.1±43.0 764.8±17.3 
 
615.3±42.3 
 
643.9±32.6 Glucagon>GLP-1 P<0.05 
GLP-1<Vehicle P<0.05 
Glucagon + GLP-1<Vehicle P<0.05 
AUC Insulin30-160 
(pmol·min/l) 
52646±6742 73606±12484 28277±6118 42841±7457 Glucagon>GLP-1 P<0.001 
GLP-1<Vehicle P<0.0001 
Glucagon + GLP-1>GLP-1 P<0.05 
Glucagon + GLP-1<Glucagon P<0.01 
AUC insulin30-160/glucose 30-
160 (pmol/mmol) 
43.3±4.8 57.5±8.0 
 
26.1±5.4 36.6±5.5 Glucagon>GLP-1 P<0.01 
Insulinogenic index 
(pmol/mmol) 
618.2±273.0 907.1±435.9 235.2±67.0 160.7±123.4  
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Table 1. Measures of glucose homeostasis during a mixed meal test 
following infusion of GLP-1, glucagon or a combination of both  
Insulinogenic index is calculated as change in insulin from T=30 to T=60, 
divided by the change in glucose from T=30 to T=60. 10 volunteers received 
each infusion. 
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2.4.4 Safety data 
2.4.4.1 Blood Pressure and Pulse 
There were no significant changes in pulse rate or blood pressure throughout the 
study (Figure 2.4). 
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Figure 2.4 Cardiovascular parameters during infusion of GLP-1, glucagon 
and combination of both. Heart rate (A), Systolic (B), and Diastolic (C) blood 
pressure changes in response to infusions. Two-way, repeated measures 
ANOVA showed no significant differences in mean between treatment groups. 
Data are mean ± SEM. 10 volunteers received each infusion. Duration of 
infusion reflected by labelled grey and hashed bar. 
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2.4.4.2 VAS results performed during acute infusion of GLP-1, glucagon or 
combination of both. 
There was no significant change in levels of nausea as measured by VAS 
(Figure 2.5). 
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Figure 2.5 VAS results performed during acute infusion of GLP-1, 
glucagon or combination of both.  
Visual analogue scores (A) How hungry do you feel right now? (B) How sick 
do you feel right now? (C) How pleasant would it be to eat right now? (D) How 
much do you think you could eat right now? (E)How full do you feel right now? 
Two-way repeated measures ANOVA showed no significant differences in 
mean VAS score between treatment groups. Data are mean ± SEM. Duration of 
infusion represented by labelled grey and hashed bar. 
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2.5 Discussion 
This clinical study, has demonstrated that the combination of GLP-1 and 
glucagon significantly attenuates the rise in pre-prandial glycaemia induced by 
glucagon alone. This is similar to previous observations by this department 
(49,201). Notably, this is the first time that infusion of GLP-1 and glucagon in 
combination has been shown to significantly reduce postprandial glycaemia 
(relative to glucagon alone) in response to a fixed meal stimulus. There was a 
further rise in glucose postprandially during the glucagon infusion, but this was 
similar to the post-prandial glucose levels during the vehicle arm. There was a 
significant reduction in AUC glucose with combination GLP-1 and glucagon, 
relative to vehicle.  
 
A previous study has shown that administration of intravenous glucagon at 3 
ng/kg/min (0.9 pmol/kg/min) in obese subjects for 6 hours did not significantly 
increase glucose levels following an OGTT, relative to saline(207). This finding 
has also been replicated in overweight subjects with a mixed meal 
stimulus(213).  The absence of postprandial hyperglycaemia in response to 
glucagon infusion compared to vehicle may be due to a compensatory rise in 
insulin, either a direct insulinotropic effect of glucagon or indirectly via a rise in 
portal concentrations of glucose. This is consistent with an earlier study of 
patients with insulin-dependent diabetes, receiving an infusion of glucagon (3 
 93 
ng/kg/min), which resulted in a significantly higher postprandial glucose 
concentrations relative to saline, implying that postprandial insulin secretion 
may be responsible for this effect(214). However, inconsistent with this in the 
current study, is the observation that there was no significant difference in AUC 
insulin comparing the glucagon alone and vehicle arms.  In addition, Frank et 
al. showed that glucagon infusion did not increase C-peptide levels compared to 
a control infusion, making a glucagon-mediated increase in insulin secretion an 
unlikely explanation(213). An alternative explanation is that there is enhanced 
hepatic glucose uptake during the glucagon infusion(215). Metabolic labelling 
studies will be necessary to study the metabolic fluxes in response to glucagon 
infusion and ingestion of a meal in order to delineate this phenomenon. 
 
The infusion of GLP-1 alone resulted in a reduction in postprandial glucose and 
insulin relative to the vehicle infusion.  The ratio of AUC insulin to AUC 
glucose and insulinogenic indices suggest that the GLP-1 infusion was the least 
insulinotropic infusion. Whilst GLP-1 is thought of as an insulinotropic 
hormone, this relative reduction in post-prandial insulin is well established and 
likely relates to slowed gastric emptying and an attenuation in postprandial 
glucose rise(106).  
 
The combination of GLP-1 and glucagon resulted in a significant reduction in 
both plasma glucose and serum insulin (as measured by AUC) relative to 
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glucagon alone. However, relative to GLP-1 alone, the dual infusion of GLP-1 
and glucagon resulted in a significantly higher AUC of glucose and insulin. 
Both GLP-1 and glucagon are known to be insulinotropic, but in our study, both 
the glucagon alone, and the combination infusion, stimulated a higher insulin 
response relative to GLP-1 alone. These observations offer a valuable insight 
into the action of these hormones in the postprandial phase.  Following RYGB, 
it has been observed that carbohydrate tolerance is improved with a significant 
rise in postprandial insulin secretion(183). As the combination infusion was a 
more potent stimulus for insulin secretion than GLP-1, the observed 
postprandial rise in glucagon after RYGB may contribute to the elevated insulin 
levels seen after this surgery.  
 
A recent study by Bagger et al also examined the physiological effects of 
glucagon plus GLP-1 combination(216). There were significant differences in 
experimental design compared to the current study. Firstly, the main 
experimental outcome in the current study  was carbohydrate tolerance, in 
contrast to energy expenditure and food intake. In the current study, the mixed 
meal challenge was initiated once the hormone infusions had achieved 
elevations of glucagon and GLP-1 at a steady state, whereas in the study by 
Bagger et al, the combined infusion and mixed meal were given simultaneously. 
Secondly, the current study was performed in an overweight population (mean 
BMI 27.2 kg/m2) whereas the cohort studied by Bagger et al. had a normal 
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BMI. The target treatment group for any dual agonist treatment would be likely 
to be obese or overweight. Lastly, the ratio of glucagon to GLP-1 dose utilised 
in our study was 3.5:1 as opposed to 0.8:1, closer to the ratio of binding 
affinities of OXM to the receptors of glucagon and GLP-1 at 2.5:1.  
 
There are several limitations to the interpretation of the current study should be 
noted. These data relate to the acute effects of GLP-1 and glucagon infusions 
and as yet the chronic effects of these hormones remain unknown. Assuming 
weight loss occurs in response to the anorexigenic effects and increase in energy 
expenditure, one would anticipate that insulin sensitivity might improve in 
response to more prolonged treatment, leading to further reductions in 
glycaemia. Furthermore, chronic glucagon administration would not be 
expected to yield a persistently elevated fasting glucose, as any increase in 
glycogenolysis should only produce a transient rise in plasma glucose and the 
glucagon-induced enhancement of gluconeogenesis is sensitive to insulin 
inhibition. Due to limitations within the study design, only fixed doses of GLP-
1 and glucagon were investigated. Future work should aim to study different 
doses hormones administered either individually or in combination in order to 
identify the optimal doses and dose ratio. Whilst the current study design 
attempted to replicate the two-fold increase in plasma glucagon concentration 
observed after RYGB, the concentration achieved was three-fold higher relative 
to fasting levels. This may suggest that glucagon concentrations observed post 
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RYGB are less likely to cause hyperglycaemia. It will be important to 
investigate whether the observed beneficial effects of a combined GLP-1-
glucagon infusion as shown in the current study translate to an obese diabetic 
population, particularly where there are limitations to stimulated insulin 
secretion. 
 
In conclusion, this study has demonstrated that the combination of GLP-1 and 
glucagon results in improved carbohydrate tolerance relative to vehicle and 
relative to glucagon alone in the context of a fixed mixed meal stimulus. These 
data provide further support for the safety of dual GLP-1 and glucagon agonists 
in the treatment of obesity and diabetes. 
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Chapter 3:         
 The acute effects of co-infusion of 
GLP-1, Oxyntomodulin and PYY on 
food intake and nausea 
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3.1 Introduction 
The dual observations that after RYGB surgery there is an elevation in 
postprandial concentrations of GLP-1, OXM and PYY, and that these hormones 
are powerful anorectic agents has led to speculation regarding a causative role 
in the metabolic benefits of RYGB surgery(102,135,157,177,180). Furthermore, 
such observations support the premise that these gut hormones could be 
developed as anti-obesity therapeutics. However, this potential has yet to be 
realised. At present the only anti-obesity medication based on a gut hormone, is 
liraglutide; a long acting GLP-1 receptor agonist(123). Further development of 
gut hormone based therapeutics has two barriers that must be overcome, a dose-
limiting nausea and a patient acceptable drug delivery process.  
 
The weight loss observed with liraglutide is relatively modest compared to 
RYGB (10% vs 30% of pre-intervention weight)(123,217). Whilst the anorectic 
effect of GLP-1 is dose-proportional, it also has a dose-limiting side-effect; 
nausea(102). Nausea has also been observed with PYY and OXM(218). One 
potential solution to overcome the nausea is to use  lower doses of single gut 
hormones in combination to achieve an an additive anorectic effect. This 
concept has been tested in studies that have co-infused PYY with GLP-1 and 
PYY with OXM, and compared their effect on food intake relative to individual 
hormone infusions(204,218). Both studies demonstrated that the co-infusion of 
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two hormones had an additive effect on food reduction but without any 
significant nausea. The success of dual infusions could be further improved by 
the co-infusion of  multiple hormones.  
 
Another potential barrier to the use of gut hormones as therapeutic agents is 
their mode of delivery.  Due to their short half life, studies investigating the 
effects of GLP-1, OXM and PYY, have used an intravenous route for 
infusion(49,102,204,218,219). An IV administration has limitations to chronic 
use. Alternative modes of delivery include SC injections. OXM has been given 
as a SC injection but due to its short half life required dosing four times per 
day(139). Long acting analogues can reduce the rate of injection; 
Bydureon(Astra Zenica, United Kingdom) (a GLP-1 long acting agonist) is 
administered once per week(220). However, at present there are no long acting 
analogues of PYY or OXM.  
 
Another alternative route of delivery is a continuous SC infusion. This route of 
drug delivery is currently used in patients with T1DM and Parkinson’s 
disease(221,222). GLP-1 has been infused by this route and resulted in weight 
loss(223). However, no study has investigated SC infusion of PYY or OXM.  
 
To address these issues, the current study was designed to investigate the effects 
of combined SC co-infusion of GLP-1, OXM and PYY, on food intake.  
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3.2 Hypothesis and aims 
3.2.1 Hypothesis 
I hypothesised that GLP-1, OXM and PYY infused in combination will reduce 
food intake without nausea. 
 
3.2.1 Aim 
To determine doses of GLP-1, OXM and PYY that could be infused together at 
a safe and tolerable dose. Subsequently, to investigate the effects of co-infusing 
GLP-1, OXM and PYY on food intake and nausea.  
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3.3 Methods 
3.3.1 Peptides 
GLP-17-37 amide, OXM and PYY were purchased from Insight Biotechnology 
limited (Wembley, UK). Representative vials were randomly selected and sent 
for microbial examination and for detection of pyrogen via a Lumulus 
Amoebocyte Lysate (LAL) test. Microbial analysis (conducted by the 
Department of Microbiology, Hammersmith Hospital, London) determined that 
the vials were sterile on bacterial and extended fungal culture. LAL testing 
(performed by Associates of Cape Cod, Liverpool, UK) determined that 
endotoxin levels were within the safe range for human infusion.  
To calculate actual peptide content, for the purpose of calculating accurate 
peptide doses, further representative vials was sent for amino acid analysis 
(Bachem, St Helens, UK). 
Further vial samples were used for toxicity studies. Forty mice were injected, 
via an IP injection at a dose 10 times greater than the maximum intended dose 
for humans (in pmol/kg body weight). Prior to sacrifice, the mice were observed 
for any abnormal behaviour. Short and long term toxicity was assessed by 
sacrificing 20 mice at 48 hours after injection and the other 20 mice 14 days 
after injection. An independent histopathologist received the following organs 
for assessment of toxicity; liver, pancreas, kidneys, heart, brain, lungs and 
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reproductive organs. 
3.3.2 Subjects 
Subjects were recruited via advertisement on the internet and newspapers.  
Inclusion criteria for the study were healthy males or females aged 18 -70 years, 
with a BMI< 50 kg/m2 and stable weight over the last three months. Exclusion 
criteria were: smokers, recreational drug users, significant past or current 
history of physical or psychiatric illness, pregnancy or breastfeeding. Prior to 
inclusion to the study all subjects were screened and determined to be healthy 
by medical history, physical examination, haematological and biochemical 
testing and 12 lead electrocardiogram.  
 
The study was approved by the West London Research Ethics Committee (ref 
no 13/LO/1510). Written informed consent was obtained for all volunteers and 
the study was carried out according to the principles of the Declaration of 
Helsinki.  
 
3.3.3 Protocol 
The study was designed as a randomised, single-blinded, placebo-controlled 
study comparing the effects of a SC co-infusion of GLP-1/OXM/PYY infusion 
to saline.  
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Whilst GLP-1 has been given as a SC infusion, there are no published studies 
investigating the effects of SC infusions of either OXM or PYY either as alone 
or in combination. During the dose finding study, doses of GLP-1, OXM and 
PYY were administrated either alone or in combination. The protocol for the 
dose finding study is shown in Figure 3.1A. A peptide infusion was commenced 
at T=0 during which a range of doses of GLP-1 (2-20 pmol/kg/min), OXM (5-
30 pmol/kg/min) and PYY (0.5-1.5 pmol/kg/min) were infused either alone or 
in combination. An ad-libitum meal was served at four hours. Regular blood 
samples, VAS scores and vital sign measurements were taken at the times 
indicated.  
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Following the dose finding study the protocol was amended to include a second 
ad-libitum meal and extended infusion duration as shown in Figure 3.1B. 
 
Subjects arrived to the clinical research facility at the Hammersmith Hospital 
having fasted overnight. Upon arrival, female volunteers were asked to pass a 
sample of urine that was tested to confirm that they were not pregnant. A 
peripheral cannula was inserted to allow blood sampling. At T=-30 minutes, a 
subcutaneous cannula (Quick-set infusion set, Meditronic, Watford, UK) was 
placed in the subject’s abdomen. At T=0 the SC infusion was started. Subjects 
received either a co-infusion of GLP-1 (4 pmol/kg/min), OXM (4 pmol/kg/min) 
and PYY (0.4 pmol/kg/min) or saline. Prior to making up the infusion, both 
syringes and infusion tubing used to deliver the hormones or saline was soaked 
in gelafusine to reduce adsorption of the peptides.  
 
The rate of infusion was delivered by a Chrono pump (Cane SPA, Rivoli, 
Italy). The infusion was continued for eight hours after a new infusion was 
started. The need for two infusions was due to the stability of GLP-1 within the 
syringe. At T= 14 the subject had their cannulae removed and was discharged 
home.  
 
Energy intake was assessed via two ad-libitum meals that were given at 
T=4hand T=10h respectively. The ad-libitum meal consisted of one of a choice 
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of 6 standardised ready meals (Sainsbury’s) of known macronutrient and 
calorific content; tomato and mozzarella pasta bake (127kcal/100g), macaroni 
cheese (189 kcal/100g), chicken tikka masala with rice (178 kcal/100g),   
chicken korma with rice (154 kcal/100g), chicken jalfrezi with rice (156 
kcal/100g) and  beef in black bean sauce with rice (130 kcal/100g). Subjects 
were given 20 minutes to eat the ad-libitum meal and were instructed to eat until 
comfortably full. For both the dose finding and main study, each volunteer was 
given the same ad-libitum meal. The weight of the food was measured pre- and 
post-meal.  
 
3.3.4 Blood assay analysis 
Insulin and glucose were measured as described in Chapter 2. Plasma active 
GLP-1 (GLP-17–36) and total PYY (PYY3–36 + PYY1–36), were prepared 
using the Milliplex MAP magnetic bead-based multi-analyte, metabolic panel, 
4-plex immunoassay (HMHMAG-34K; Millipore, St. Charles, MO, USA) and 
measured using Luminex Magpix with xPONENT software (Luminex 
Corporation, Austin, TX, USA). The kit is a capture sandwich immunoassay 
which uses a capture antibody attached to a microsphere and a detection 
antibody that incorporates a fluorescent label.  
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OXM was measured by the Panum Institute, Kobenhavn University, Denmark, 
using an in-house radio-immunoassay. 
 
3.3.5 Statistical analysis 
Two-way repeated ANOVA with Bonferroni post hoc test were used to 
compare differences in glucose, insulin, and changes in blood pressure and 
pulse. A paired t- test was used to analyse changes in food intake. Results are 
presented as mean ± SEM and statistical significance was defined as P<0.05. 
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3.4 Results 
3.4.1 Dose finding study investigating the acute effects of GLP-1, 
OXM and PYY on energy intake and nausea in humans. 
A dose finding study was undertaken to determine the appropriate subcutaneous 
dose of GLP-1, OXM and PYY that could reduce food intake without nausea 
compared to saline. The dose finding study took part in three phases. The first 
phase was a parallel arm study in which single infusions of GLP-1, OXM and 
PYY were given. The second phase involved the use of combined infusion of 
GLP-1 and OXM. The final phase was co-administration of all three hormones. 
  
3.4.1.1 Investigation of infusions of subcutaneous GLP-1, OXM or PYY 
alone on food intake and nausea 
The effects of GLP-1, OXM and PYY infusions, administered alone, were 
tested to determine the effects on food intake (Figure 3.2) and nausea (Table 
3.1).  
 
The lowest effective dose of GLP-1 that was tolerated in terms of nausea was 16 
pmol/kg/min. Both 20 and 30 pmol/kg/min doses of OXM were effective at 
reducing food intake relative to saline but less nausea was observed in those 
receiving 20 pmol/kg/min. Tolerable doses of PYY were lower than both GLP-
1 and OXM. Both 1.0 and 1.5 pmol/kg/min doses of PYY were anorectic but 
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more nausea was observed with 1.5 pmol/kg/min.
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Figure 3.2 Percentage reduction in food intake following subcutaneous 
administration of GLP-1 (A), OXM (B) and PYY (C) relative to saline. 
Volunteers received an infusion of either saline (control) or one of the following 
hormones; GLP-1, OXM or PYY. The infusion duration was eight hours. An 
ad-libitum meal was given four hours after the infusion was started. The number 
of volunteers who received each infusion is shown in brackets. 
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Table 3.1 Investigation of the effects of varying doses of subcutaneous 
infusions of GLP-1, OXM or PYY alone on nausea. Volunteers received 
infusions of GLP-1, OXM and PYY at different doses for a duration of eight 
hours. Nausea was either recorded on VAS score sheets at specific time points 
or reported to the investigator if occurring between time points.  
  
Peptide Dose 
(pmol/kg/min) 
Number of 
subjects 
Number of 
subjects with 
nausea 
GLP-1 2-8 1 0 
12 5 1 
16 4 1 
20 3 3 
OXM 5-15 1 0 
20 8 0 
30 4 2 
PYY 0.5 1 0 
1.0 3 1 
1.5 3 2 
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3.4.1.2 Investigation of the acute effects of subcutaneous co-administration 
of GLP- 1 and OXM on food intake and nausea. 
Further dose finding was performed to determine the effect of co-infusion of 
GLP-1 and OXM. Doses of 16 and 20 pmol/kg/min of GLP-1 and OXM were 
selected based on the results of the previous dose finding study. However, as 
both peptides are infused via a single pump that uses one infusion rate for both 
peptides, it was more practical to infuse 15 and 20 pmol/kg/min of GLP-1 and 
OXM.  Whilst this dose was effective at reducing food intake (Figure 3.3) there 
was a high rate of nausea (Table 3.2) and so both peptide doses were reduced to 
12 pmol/kg/min. This combination at a lower dose produced less nausea.  
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 Figure 3.3 Percentage reduction in food intake achieved by subcutaneous 
co-infusion of GLP-1 and OXM at varying doses relative to saline. 
Volunteers received an infusion of either saline or co-infusion of GLP-1 and 
OXM. The infusion duration was eight hours. An ad-libitum meal was given 
four hours after the infusion was started. The number of volunteers who 
received each infusion is shown in brackets. 
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Dose of GLP-1/OXM 
(pmol/kg/min) 
Number of subjects Number of subjects with 
nausea 
12/12 3 0 
15/20 5 4 
 
Table 3.2 Effect of different doses of combined subcutaneous infusions of 
GLP-1 and OXM on nausea. Volunteers received co-infusions of GLP-1 and 
OXM for a duration of eight hours. Nausea was either recorded on VAS score 
sheets at specific time points reported to the investigator if occurring between 
time points. 
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3.4.1.3 Investigation of the acute effects of subcutaneous co-administration 
of GLP-1, OXM and PYY on food intake and nausea. 
The final dose finding phase aimed to identify a tolerable dose of each peptide 
when co-infused together. Whilst co-infusion of GLP-1 and OXM (each at 12 
pmol/kg/min) was well tolerated, both doses were reduced 6 pmol/kg/min 
before addition of PYY. The rationale for this was that the experience from 
moving to single to combination infusions had demonstrated that nausea was 
induced at lower doses when multiple hormones were co-infused.  
 
The first trial dose for triple peptide infusion was 6, 6 and 0.5 pmol/kg/min of 
GLP-1, OXM and PYY respectively. The effects of this combination on food 
intake and nausea are shown in Figure 3.4 and Table 3.3. Since administration 
of this combination at these doses produced nausea, subsequent peptide doses 
were reduced to 4 , 4 and 0.4 pmol/kg/min respectively. This combination of 
doses reduced food intake but produced less nausea.  
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Figure 3.4 Effect of subcutaneous co-administration of GLP-1, OXM and 
PYY at varying doses on food intake. Volunteers received a combined 
infusions of GLP-1, OXM and PYY infusion or saline. The infusion duration 
was eight hours. An ad-libitum meal was given four hours after the infusion was 
started. The number of volunteers who received each infusion is shown in 
brackets. 
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Dose of GLP-1/OXM/PYY 
(pmol/kg/min) 
Number of subjects Number of subjects with 
nausea 
6/6/0.5 2 2 
4/4/0.4 3 0 
Table 3.3 Effect of subcutaneous co-infusions of GLP-1, OXM and PYY of 
varying doses on nausea. Volunteers received co-infusions of GLP-, OXM and 
PYY at varying doses for a duration of eight hours. Nausea was either recorded 
on VAS score sheets at specific time points or reported to the investigator if 
occurring between time points.  
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3.4.2 Investigation of the acute effects of subcutaneous co-
administration of GLP-1, OXM and PYY on food intake and 
nausea. 
Co-administration of GLP-1, OXM and PYY resulted in a significant reduction 
in mean total food intake (meal 1 and meal 2) relative to saline (mean total food 
intake 1027±145 [GLP-1/OXM/PYY] vs 1528±152 kcal [saline] P<0.05, Figure 
3.5). 
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 Figure 3.5 Energy intake following ad-libitum meal in human subjects. 
Participants were given a meal of known quantity and calorie content during an 
infusion of saline or GLP-1, OXM and PYY (GOP) (4/4/0.4 pmol/kg/min). 
Data were analysed using a paired t test. * P<0.05. N = 5. Meals 1 and 2 were 
ad-libitum meals, was given four and eight hours after the infusion was started.  
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3.4.2.2 Investigation of the acute effects of subcutaneous co-administration 
of GLP-1, OXM and PYY on nausea and satiety. 
During the GLP-1, OXM and PYY infusions, one volunteer developed nausea 
four hours after the infusion was started. No other volunteer receiving the co-
infusion of peptides had nausea. There was no significant difference in VAS 
scores between those receiving co-infusion of GLP-1, OXM and PYY relative 
to saline (Figure 3.6).  
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Figure 3.6 Change from baseline in visual analogue scale (VAS) scores in 
subjects. VAS scores were measured at each time point in response to the 
following questions: (A) ‘How hungry do you feel right now?’, (B) ‘How sick 
do you feel right now?’, (C) ‘How pleasant would it be to eat right now?’, (D) 
‘How much do you think you could eat right now?’, (E) ‘How full do you feel 
right now?’ and (F) ‘How tasty was the meal?’. Volunteers received either an 
infusion of GLP-1,OXM and PYY ( 4/4/0.4 pmol/kg/min) or saline for 14 hours 
minutes. Data were analysed with two-way repeated measures ANOVA with 
Bonferroni post test (A-E). Abbreviations: GLP-1, OXM and PYY (GOP). 
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3.4.2.3 Investigation of the gut hormone levels following an acute 
subcutaneous co-administration of GLP-1, OXM and PYY.  
Prior to infusion, mean plasma concentration of GLP-1 was 4.0±1.5 pmol/l 
(Figure 7). Two hours after the infusion was started, a peak plasma GLP-1 
concentration of 18.7±6.0 pmol/l was achieved. There was no significant rise in 
the concentration of GLP-1 in the volunteers when infused with saline. 
 
Mean fasting concentration of OXM was 41.0±9.0 pmol/l. This rose to a mean 
peak concentration of 120.0±20.0 pmol/l, two hours after the combined infusion 
was initiated. Samples taken from subjects receiving saline were not measured 
due to the limited amount of samples I was able to send to my collaborators.  
 
Before the combined infusion was started, the mean basal concentration of PYY 
was 22.4±3.8 pmol/l. Mean peak concentration was achieved six hours after the 
start of the infusion at 56.2±1.3 pmol/l. There was no significant rise in the 
concentration of PYY in the volunteers when infused with saline. 
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Figure 3.7 
 Mean plasma concentration of GLP-1 (A), OXM (B) and PYY (CC) during 
infusion of GLP-1, OXM and PYY. Subjects were infused with GLP-1, OXM 
and PYY for 14 hours. Samples for hormone measurement were taken at the 
times indicated. N = 5 
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3.4.2.3 Investigation of the acute effects of subcutaneous co-administration 
of GLP-1, OXM and PYY on glucose and insulin. 
The mean baseline plasma glucose in all subjects was 5.3±0.1 mmol/l prior to 
infusion (Figure 3.8). Mean plasma glucose concentration rose after both ad-
libitum meals. However, there was no significant difference in plasma glucose 
concentration in subjects receiving co-infusion of GLP-1, OXM and PYY 
(4/4/0.4 pmol/kg/min) relative to saline throughout the duration of 14 hour 
infusion. 
  
Mean baseline serum insulin concentration for all subjects was 11.9±1.4 mIU/L 
in all subjects prior to infusion. Insulin concentration increased in response to 
the elevation in post=prandial plasma glucose but there was no significant 
difference between the two infusion groups 
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Figure 3.8 Comparison of changes in glucose (A) and insulin (B) following 
co-infusion of GLP-1, OXM and PYY. Volunteers received a combined 
infusion of either GLP-1, OXM and PYY (GOP) (4/4/0.4 pmol/kg/min) or 
saline. Glucose and insulin samples were collected at the time points indicated 
and two ad-libitum meals were consumed at the four and eight hours after 
infusion was started. Data was analysed using two-way ANOVA with 
Bonferroni post hoc test. Number of volunteers in each group shown in 
brackets. 
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3.4.2.4 Investigation of the acute effects of subcutaneous co-administration 
of GLP-1, OXM and PYY on cardiovascular parameters. 
There was no significant difference in pulse rate or systolic and diastolic blood 
pressure in subjects receiving co-infusion of GLP-1, OXM and PYY relative to 
saline (Figure 3.9). 
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Figure 3.9 Changes in pulse rate (A), systolic (B) and diastolic (C) blood 
pressure following co-infusion of GLP-1, OXM and PYY relative to saline. 
Subjects were infused over 14 hours a co-infusion of GLP-1, OXM and PYY 
(4/4/0.4pmol/kg/min) or saline or Data were analysed using two-way ANOVA 
with Bonferroni multiple post hoc test. Number of subjects in each group shown 
in brackets. 
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3.5 Discussion 
This study demonstrates that co-infusion of GLP-1, OXM and PYY can 
significantly reduce food intake. This data is novel for two reasons. Firstly, it is 
the first study to investigate the co-infusion of these three gut hormones. 
Secondly, whilst there are data on the use of a continuous SC pump to deliver 
GLP-1, this route of administration has not studied previously with PYY or 
OXM(223). The anorectic effect demonstrated supports the further development 
of delivering these gut hormones in combination as a treatment for obesity in 
humans. 
 
Co-infusion of GLP-1, OXM and PYY resulted in a mean reduction in total 
energy intake of 501±128 kcal. This is equivalent to a 32.8% reduction in daily 
food intake. This reduction in food intake is comparable to 34% reduction in 
calorie intake observed in RYGB patients 2 years post surgery(224). If future 
work demonstrates that the reduction in food intake with co-infusion of GLP-1, 
OXM and PYY is sustained, this could provide an alternative treatment for 
obesity to surgery.  
 
This is the first study in man to infuse three gut hormones together to study the 
effects on food intake. Others have previously co-infused two gut hormones. 
Field et al used a combination of OXM and PYY whilst Neary et al co-infused 
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GLP-1 and PYY(204,218). These studies demonstrated reductions in energy 
intake of 43 and 27% respectively but neither is directly comparable to the 
current investigation due to differences in both the route of administration as 
well as the doses used. Both previous studies demonstrated that the co-infusion 
was additive in its anorectic effect, by comparing the co-infusion to single 
hormone infusion. The data from this study cannot provide further insight into 
the additive anorectic as single infusions were not employed beyond the dose 
finding stage. However, during the dose finding period, it was necessary to 
reduce the doses of gut hormones administered each time a new gut hormone 
was added to the co-infusion due to nausea. This suggests that the effects of the 
triple hormone co-infusion may be additive but further controlled studies will 
need to be performed to confirm this.  
 
Only one of the five subjects experienced nausea during the triple hormone 
infusion. However, if the cohort size was larger, there may have been more 
nausea observed. A future larger study would be able to address this further.  
 
Whilst the primary outcome of this study was been food intake, an alternative 
mechanism to achieve weight loss is through increasing energy expenditure.  It 
has been shown that specific gut hormones such as glucagon and OXM can 
induce an increase in energy expenditure(49,137). An increase in energy 
expenditure is also observed after RYGB surgery which may be related to the 
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increased concentration of OXM and glucagon post surgery(225). Determining 
whether a co-infusion containing OXM can also increase energy expenditure is 
an important step in developing it as an anti-obesity therapeutic. 
 
There are specific limitations to this study that should be noted. Only a small 
cohort of five patients was used and the study was only single-blinded. Further 
more whilst the duration of the infusion was longer than in most studies 
investigating the effects of gut hormones on food intake (mean duration was 60 
minutes), it would be useful to assess whether the anorectic effect is maintained 
beyond 24 hours(102). A final limitation was the absence of oxyntomodulin 
concentrations in those receiving saline.  
 
In conclusion, this study has shown that a subcutaneous combined infusion of 
GLP-1, OXM and PYY can reduce food intake in healthy obese human 
volunteers. This is an important step in the development of combination gut 
hormones as anti obesity treatments. Future work should evaluate the effects of 
a triple hormone infusion on energy expenditure, and determine whether the 
observed energy intake reduction persists when administered over the longer 
term.  
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Chapter 4  
The role of gut hormones in the 
pathophysiology of postprandial 
hypoglycaemia 
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4.1 Introduction 
In Chapters 2 and 3 I have demonstrated that administration of gut hormones 
can result in improvements in carbohydrate tolerance and a reduction in food 
intake. This data supports the role that the elevated postprandial concentration 
of gut hormones post RYGB may contribute to the improvement in weight and 
diabetes that occur after the operation. Furthermore, it supports the use of gut 
hormones as a potential treatment for obesity and diabetes. However, if gut 
hormones are responsible for the metabolic benefits after RYGB they may also 
account for some of the metabolic complications that occur too. 
 
Laparoscopic RYGB is considered a relatively safe surgical procedure with a 
morbidity and mortality of 0.16% which is similar to low risk surgery such as 
laparoscopic cholecystectomy(226). However, as the operation is becoming 
more frequently performed to match the rise in obesity prevalence, unusual 
metabolic complications are becoming more recognised. These include 
nutritional deficiencies such as pernicious anaemia which is likely related to the 
reduction in gastric size and other conditions such as a loss of bone mass that at 
present has no clear pathogenic mechanism(227,228). PPH, in which patients 
develop low glucose concentrations after eating is another metabolic 
complication of RYGB that has implicated gut hormones as a potential 
cause(184). 
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PPH is considered a relatively new phenomenon having first been described by 
Service et al in 2005 in 6 patients(187). However, there have been case reports 
and series of PPH occurring after partial gastrectomies (for gastric ulcer 
disease) that have been reported since the 1930s(229). Whilst the bariatric and 
dyspeptic operations differ in technique, the alteration in postprandial glucose 
profile is common in both and a similar pathophysiology is likely.  
 
PPH may reflect an extreme instance of the changes in glucose homeostasis that 
occurs after RYGB. After surgery there is a dramatic alteration in glucose 
tolerance(230). Beyond a reduction in fasting and postprandial plasma glucose 
levels, there is also a change in the glucose tolerance curve. Instead of a steady 
rise in plasma glucose that plateaus before returning to baseline, there is a sharp 
rise with a peak glucose at 30 minutes with a subsequent rapid drop(230). In 
patients with PPH the rapid decrease in glucose concentrations can result in 
hypoglycaemia. It remains unclear why certain patients post RYGB develop 
PPH whilst others do not.  
 
The rapid oscillations in postprandial glucose demonstrate the significant 
increase in glucose variability that occurs post RYGB.  This increase in 
glycaemic variability after RYGB has been documented with the use of 
continuous glucose monitoring, relative to obese subjects who have not had 
RYGB surgery(231). Increased glycaemic variability is not exclusive to patients 
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who have diabetes prior to surgery but also occurs in patients with no prior 
history of diabetes. It is unclear if RYGB patients with PPH have increased 
glycaemic variability relative to RYGB patients who do not.  
 
Whilst the cause behind PPH remains unclear, it has been established that the 
hypoglycaemia is hyperinsulinemic in nature(232). Post RYGB there is a rapid 
postprandial rise in insulin but the mechanism underlying the increased insulin 
secretion remains unknown(233). Previous work has focused on incretins 
(insulinotropic hormones that are secreted in response to an oral glucose load) 
and in particular GLP-1. Some studies have shown elevated postprandial GLP-1 
levels in patients with PPH relative to asymptomatic patients whilst others have 
failed to confirm this(184,234). Furthermore, both GLP-1 antagonists and 
agonists have been shown to improve PPH(191,235). As such, the role of gut 
hormones including GLP-1 in the pathophysiology of PPH remains unclear and 
requires further investigation.  
 
  
 139 
4.2 Hypothesis and Aims 
4.2.1 Hypothesis 
I hypothesise that patients with PPH after RYGB have increased glycaemic 
variability and that this is associated with changes in levels of gut hormones. 
4.2.2 Aims 
My aims were to investigate a cohort of patients with PPH: 
1. To measure their glycaemic variability using continuous glucose 
monitoring. 
2. To measure the secretion of postprandial gut hormones. 
3. To examine the relationship of postprandial gut hormone secretion to the 
type of meal stimulus. 
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4.3 Methods 
4.3.1 Subjects 
Subjects were recruited from the Imperial Weight Centre who were referred 
with symptoms suggestive of PPH. For inclusion to the study patients must have 
either autonomic (this includes symptoms such as sweaty, palpations tremor) or 
neuroglycopenic symptoms (such as drowsiness, pre-syncope, or loss of 
consciousness). These symptoms had to occur within five hours after eating and 
resolved with carbohydrate ingestion. Exclusion criteria were any current 
medication known to affect glucose metabolism or a history of symptoms that 
predated the operation.  
 
The study was done as part of routine clinical care for patients suspected to have 
PPH and as such no ethical approval was required.  
 
Previous studies that have investigated PPH have compared bariatric surgery 
patients who are known to have symptoms of PPH with a group of 
asymptomatic patients(236,237). However, in many of these studies, it is 
apparent that during the provocation test used in the studies not all the 
symptomatic group had a hypoglycaemia and at the same time, some of the 
asymptomatic group appear to have a biochemical hypoglycaemia without 
symptoms. This illustrates two important observations. First, in the RYGB 
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cohort, there is a high prevalence of asymptomatic hypoglycaemia. Secondly, in 
those patients who have previously shown to have PPH, the reproduction of this 
condition appears variable.  
 
If a patient who has previously been demonstrated to have PPH undergoes a 
provocation test but does not experience biochemical hypoglycaemia, it is 
possible that the hormonal changes that may cause PPH are not present during 
that study.  As the aim of the current study was to determine if gut hormones are 
associated with biochemical hypoglycaemia, subjects were subdivided into 
those that had biochemical hypoglycaemia during a given provocation test and 
their gut hormone response to a provocation test was compared to those that did 
not experience hypoglycaemia . 
 
4.3.2 Continuous Glucose Monitoring 
Two types of continuous glucose monitor (CGM) were used.  
1. Medtronic iPro2  
2. Abbott Navigator® II  
The Medtronic iPro2 CGM was the initial choice for continuous glucose 
monitoring but because of a high sensor failure rate, subsequently the Navigator 
II2 CGM was used. 
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Subjected were asked to wear a CGM for 5 days. Both the Medtronic iPro2 
and Abbott Navigator II comprise a light-weight memory storage unit which 
is attached to a sensor. Using a spring-loaded device, the sensor is placed in the 
subcutaneous layer of tissue of the abdomen where it measures glucose 
concentrations in interstitial fluid. Both sensors measure interstitial glucose 
using an amperometric enzyme electrode based on the glucose oxidase 
reduction-oxidation reaction. The Medtronic iPro2 measures glucose at 5 
minute intervals whilst the Abbott Navigator II has a 10 minute interval.  
 
For both CGMs, subjects were asked to measure their capillary blood glucose 
(CBG) using the finger prick method, in order to calibrate their machine. They 
were provided with Abbott Freestyle Lite blood strips for this purpose. For the 
Medtronic iPro2, subjects were asked to perform a minimum of 3 CBG 
measurements per day. For the Abbott Navigator II, subjects were asked to 
perform CBG at 1, 2, 10, 24 and 72 hours after the sensor was inserted. 
 
After five days of wearing the sensor, the subjects returned the CGM storage 
unit. The data was uploaded onto internet-based platforms (Carelink and 
Freestyle Copilot for iPro2 and NavigatorII respectively), which use 
proprietary algorithms to relate capillary glucose measurements to subcutaneous 
interstitial fluid glucose measurements. 
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The recorded data were analysed for mean glucose and glycaemic variability 
measures including Mean Amplitude Glycaemic Excursions (MAGE), 
Continuous Overlapping Net Glycaemic Action (CONGA), Mean of Daily 
Differences (MODD) and risk indices such as Low Blood Glucose Index 
(LBGI), High Blood Glucose Index (HBGI) and Average Daily Risk Ratio 
(ADRR). These values were calculated using the easyGV 9.0 software(238). 
The equations used to calculate these measures of glycemic variability are 
shown in Table 4.1. 
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Variability 
measure 
Formula Discriminating feature 
MAGE  
 
 
Used most extensively 
CONGA 
 
 
 
Specifically developed for CGM 
MODD 
 
 
Assess intra-day variability 
LBGI 
 
Gives a risk score for hypoglycaemia 
HBGI 
 
Gives a risk for hyperglycaemia 
ADDR 
 
Gives a measure of glycaemic control 
Table 4.1 Measures of glycaemic variability. MAGE=mean amplitude 
glucose excursion; CONGA=continuous overlapping net glycaemic action; 
MODD=mean of daily differences, HBGI= high blood glucose index; 
LBGI=low blood glucose index, ADRR =average daily risk. λ = blood glucose 
changes from peak to nadir χ = number of observation ν = 1 standard deviation 
of mean glucose for a 24 hour period κ = total number of observations rl = risk 
value associated with a low glucose (if χ<0), rh= risk value associated with high 
glucose (if χ>0), χI = nonlinear transformation of glucose measured, LR = risk 
value attributed to low glucose HR = risk value attributed to high glucose. 
Adapted from Siegelaar et al.(239) 
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The normal reference values for a non diabetic population are shown in Table 
4.2. 
 Lower limit Upper limit 
MAGE 0.0 2.8 
CONGA 3.6 5.5 
MODD 0.0 3.5 
LBGI 0.0 6.9 
HBGI 0.0 7.7 
ADRR 0.0 8.7 
Table 4.2 Normal reference range for measures of glycemic variability. 
MAGE=mean amplitude glucose excursion; CONGA=continuous overlapping 
net glycaemic action; MODD=mean of daily differences, HBGI= high blood 
glucose index; LBGI=low blood glucose index, ADRR =average daily risk 
ratio. Adapted from Nathan Hill et al(240) 
 
4.3.3 Mixed Meal Test (MMT) Study  
Patients arrived at the planned investigation unit at 0830h having fasted from 
2200h the night before. Upon arrival, subjects had a peripheral venous cannulae 
inserted for the purpose of blood sampling. At 0900h subjects were given an 
Ensure Plus (13.8 g of protein, 10.8 g of fat, 44.4 g of carbohydrates, 330 
kcal, 220 ml, Abbott, Maidenhead, UK) to consume. They were advised to 
consume the Ensure Plus within 10 minutes and were observed by the 
investigator to confirm complete consumption. Blood sampling for glucose, 
insulin, C-peptide and gut hormones were taken at the following time points, 0, 
30, 60, 90, 120, 150, 180, 210 and 240 minutes. Vacutainer tubes (International 
Scientific Supplies Ltd, Bradford, UK) containing clot activators and fluoride 
oxalate tubes were used to collect insulin and glucose samples respectively. For 
the purpose of collecting gut hormones, lithium heparin-coated BD Vacutainer 
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tubes were prepared with the addition of 1000 kallikrein inhibitor units (0.1ml) 
(Trasylol, Bayer Schering Pharma, Berlin, Germany). Samples were stored on 
ice until centrifugation (4oC, 4000 rpm, 10 minutes) after which, plasma was 
separated immediately and stored at -20oC until analysis. In addition, a CBG 
sample was taken if subjects complained of symptoms of hypoglycemia.  Blood 
pressure and pulse were also measured at those time points. The study was 
stopped if subjects developed neurological symptoms of hypoglycemia and had 
a capillary blood glucose less than 2.0 mmol/l. Biochemical hypoglycemia was 
defined as a venous plasma glucose <3.0 mmol/l in keeping with the consensus 
guidelines on hypoglycemia (241).  
 
4.3.4 Prolonged Oral Glucose Tolerance Test (POGTT) 
The protocol for the prolonged oral glucose tolerance test was identical to the 
mixed meal test aside from the use of an oral 75 g glucose load in substitution 
for the Ensure Plus. The oral glucose challenge was prepared by dissolving 75 
g of anhydrous glucose in 500 ml of water.  
 
4.3.5 Glucose, Insulin and C-peptide assays 
Glucose, insulin and C-peptide samples were measured by the Department of 
Chemical Pathology, Imperial College Healthcare National Health Service 
Trust. Plasma glucose was assayed using an Abbott Architect automated 
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analyzer (Maidenhead, UK), utilizing a hexokinase-glucose-6-phosphate 
dehydrogenase method. The analytical range was 0.278–44.4 mmol/L, with an 
intra-assay coefficient of variation of 0.65–1.98% and an inter-assay coefficient 
of variation of 0.84–0.93%. Serum insulin levels were measured on an Abbott 
Architect platform using Abbott reagents with an inter-assay coefficient of 
variation of 10%.  
 
4.3.6 Gut Hormone assays 
Plasma active GLP-1 (GLP-17–36), total PYY (PYY3–36 + PYY1–36), GIP 
and Glucagon were measured using the Milliplex MAP magnetic bead-based 
multi-analyte, metabolic panel, 4-plex immunoassay (HMHMAG-34K; 
Millipore, St. Charles, MO, USA) and Luminex Magpix with xPONENT 
software (Luminex Corporation, Austin, TX, USA). The manufacture protocol 
was used (Appendix B). The cross reactivity between the antibody for glucagon 
and oxyntomodulin is 0.7%. The kit is a capture sandwich immunoassay in 
which a capture antibody is attached to a microsphere and a detection antibody 
that incorporates a fluorescent label.  
 
4.3.7 Statistical Analysis 
Two-way repeated measures ANOVA with Bonferroni post hoc test was used to 
compare differences in glucose, insulin, active GLP-1, GIP, PYY and glucagon 
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at different time points. One-way ANOVA with Tukey post hoc test was used to 
compare differences in AUCs when more than two groups were being 
compared. Unpaired Student t-tests were used to compare differences between 
groups when only two groups were being compared. When data was not 
normally distributed (assessed by D’Agostino-Pearson omnibus normality test) 
due to small number, a Mann-Whitney test was used. Results are presented as 
mean ± SEM and statistical significance defined as P<0.05.  
4.4 Results 
4.4.1 Demographics of subjects  
The demographics of the subjects recruited for the study are shown below in 
Table 4.3. Sixteen subjects who had symptoms suggestive of PPH after RYGB 
were classified as symptomatic RYGB. Two control groups were also analysed; 
a group of obese patients who had not had RYGB surgery (obese no-RYGB) 
and a group consisting of RYGB patients who had not had symptoms of PPH 
(asymptomatic RYGB). Further details on the volunteers with PPH are shown 
in Table 4.4.  
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 Symptomatic 
RYGB 
Obese-No RYGB Asymptomatic 
RYGB 
Number of 
subjects 
16 9 5 
Gender 9F 7M 7F 2M 4F 1M 
Age (years) 48.2±2.5 43.6±3.9 41.8±3.6 
HbA1c (mmol/l) 38.4±1.2 39.8±1.7 37±2.2 
Years since 
surgery (years) 
2.5±1.4  2.6±0.7 
Presurgical weight 
(kg) 
127.3±5.7  134.7±4.8 
Percentage weight 
loss at 1 year(%) 
30.8±7.9  29.8±6.9 
Table 4.3 Demographics of subjects in study. F=Female, M=Male. 
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Table 4.4 Demographics of PPH subjects. 16 subjects who were suspected of having PPH were investigated in this 
study 
Patient 
No. 
Year of 
Surgery 
Type of Surgery Age 
(years) 
Diabetes pre 
surgery 
Presurgical weight 
(Kg) 
Percentage weight loss 
at 1 year (%) 
Onset of symptoms from 
surgery (years) 
1 2010 RYGB 50 Yes 117 32 2 
2 2010 RYGB 52 No 130 37 1 
3 2007 RYGB 44 Yes 126 41 3 
4 2007 RYGB 26 No 151 27 3 
5 2010 RYGB 44 Yes 131 33 2 
6 2010 RYGB 60 No 118 28 1 
7 2006 Oesphagectomy and 
Roux-en-Y 
anastomosis 
46 No 90 20 4 
8 2011 RYGB 52 Yes 127 35 2 
9 2010 RYGB 51 yes 98 38 1 
10 2005 Gastrectomy for 
peptic ulcer disease 
49 No 101 26 7 
11 2012 RYBB 46 yes 118 29 1 
12 2012 RYGB 49 No 167 31 1 
13 2010 RYGB 71 Yes 121 36 3 
14 2011 RYGB 43 Yes 153 43 2 
15 2013 RYGB  33 No 168 25 1 
16 2012 RYGB (conversion 
from sleeve) 
55 No 121 12 2 
 151 
4.4.1 Investigation into glycaemic variability in patients with PPH  
Seven subjects (patient numbers 2, 3, 5, 7, 9, 11 and 13 from table 4.4)  who 
had symptoms of PPH post RYGB wore CGMs for five days. Their data was 
compared to three RYGB patients who were asymptomatic for PPH (Table 4.5) 
There were no significant differences in the presurgical weight or percentage 
weight loss between the two groups. There was no significant difference 
between the two groups CGM data, although the MAGE score approached 
significance.  
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 GV Measure Asymptomatic 
(N=3) 
Symptomatic (N=7) P value 
Mean (mmol/l) 5.49±0.42 6.12±0.24 0.20 
SD 1.78±0.57 2.04±0.23 0.61 
MAGE 2.39±0.69 4.93±0.75 0.07 
CONGA 4.76±0.50 5.05±0.19 0.52 
LBGI 4.84±1.46 3.49±0.70 0.37 
HBGI 4.61±3.29 4.36±2.72 0.93 
% time in 
hypoglycaemia <3.0 
2.1±1.6 1.0±0.6 0.48 
% time in range, 
3.0-7.0 
85.1±4.8 74.2±3.4 0.11 
% time in 
hyperglycemia >7.0 
12.8±3.6 21.9±5.2 0.29 
Table 4.5 Comparison of measures of glycaemic variability between 
patients with PPH and those without. 
Differences in measures of glycaemic variability (GV). There were no 
significant differences in the methods used. SD=standard deviation; 
MAGE=mean amplitude glucose excursion; CONGA=continuous overlapping 
net glycaemic action; HBGI= high blood glucose index; LBGI=low blood 
glucose index.  
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4.4.2. Comparison of changes in glucose and insulin following a 
Mixed Meal Test in patients suspected of having PPH  
Thirty subjects underwent a MMT. The subjects were separated into three 
groups; 
• 16 subjects with symptoms of PPH (Symptomatic RYGB) 
• 5 subjects who had had RYGB surgery but had no symptoms of PPH 
(Asymptomatic RYGB) 
• 9 subjects who were obese but had not had RYGB (Obese-No RYGB). 
There was no significant difference in the fasting glucose concentration in all 
three groups (Figure 4.1A and Table 4.6).  Thirty minutes following the 
consumption of the mixed meal, there was a significant difference in plasma 
glucose concentration between both surgical cohorts relative to Obese-No 
RYGB group (Glucose30: 9.4±0.8 [Symptomatic RYGB] vs 6.1±0.4 mmol/l 
[Obese-No RYGB], P<0.05; 10.3±1.9 [Asymptomatic RYGB] vs 6.1±0.4 
mmol/l [Obese-No RYGB], P<0.05).  
 
There was no significant difference in the concentration of fasting insulin 
between all three groups (Figure 4.1B and Table 4.6). Thirty minutes following 
the consumption of the mixed meal, there was a significant difference in serum 
insulin concentration between both surgical cohorts relative to Obese-No 
RYGB group (Insulin30: 130.2±24.7 [Symptomatic RYGB] vs 39.9±7.7 mU/l 
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[Obese-No RYGB], P<0.05; 152.5±44.3 [Asymptomatic RYGB] vs 39.9±7.7 
mU/l [Obese-No RYGB], P<0.05). Both RYGB groups concentration of serum 
insulin returned to baseline at 120 minutes whilst the Obese-No RYGB group’s 
serum insulin was elevated till 180 minutes. 
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Outcome measures Symptomatic 
RYGB (N=16) 
Obese-No RYGB 
(N=9) 
Asymptomatic RYGB 
(N=5) 
Mean fasting glucose 
(mmol.l-1) 
4.8±0.2 5.0±0.3 5.1±0.2 
Mean peak glucose 
(mmol.l-1) 
9.8 ± 0.7 7.1 ± 0.3 10.8 ± 1.5* 
Mean nadir glucose 
(mmol.l-1) 
3.4 ± 0.2 4.1 ± 0.1 4.3 ± 0.5 
 Mean glucose30 
(mmol.l-1) 
9.4 ± 0.8* 6.0 ± 0.4 10.3 ± 1.9* 
Mean time to peak 
glucose (min) 
35.6 ± 3.0* 80.0 ± 13.2 42.0± 12.0* 
Mean time to nadir 
glucose (min) 
146.3 ± 20 220 ± 14.1 120.0±28.5 
Mean AUC glucose 
(mmol.l-1.min) 
1346.7±82.9 1333.3±57.4 1485±81.4 
Fasting insulin (mU.l-
1) 
7.0±0.1 9.6±1.0 10.4±2.1 
Mean peak insulin 
(mU.l-1) 
139.0± 23.1 61.1 ± 9.1 178.4 ± 51.0* 
Mean insulin30 (mU.l
-
1) 
130.2 ± 24.7* 39.9 ± 7.7 152.5 ± 44.3* 
Mean time to peak 
insulin (min) 
39.4 ± 4.5* 73.3±12.4 42.0 ± 7.3 
Mean AUC insulin     
(mU.l-1.min)   
8233.3±1004.4 
 
6729.2±988.9 13004.6±4159.0 
Table 4.6 Comparison of measures of glucose homeostasis following a 
mixed meal in symptomatic RYGB group, a non- surgical obese group and 
an asymptomatic RYGB group. Significant differences are *  vs Obese No 
RYGB, P < 0.05.  
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4.4.3 Investigation into changes in glucose and insulin in PPH 
patients: Hypo vs Non-Hypo groups   
Six of the 16 patients referred with symptoms suggestive of PPH had plasma 
glucose concentrations below 3.0 mmol/l following a MMT (Table 4.7). In 
order to further investigate what causes PPH in a post RYGB patient, the 
subjects data was categorised into those that had biochemical hypoglycaemia 
(MMT Hypo) and those that did not (MMT Non-hypo).  
 
Glucose and insulin responses to the MMT are shown in Figure 4.2 and Table 
4.8. There was no significant difference in baseline plasma glucose 
concentrations between those that did and did not have biochemical 
hypoglycaemia. As expected, the MMT Hypo group had a significantly lower 
nadir glucose relative to the MMT Non-hypo group (Nadir glucose 2.39±0.19 
[MMT-Hypo group] vs 3.40±0.16 mmol/l [MMT-Non-Hypo group]). With 
reference to the glycaemic profile there was no other significant difference 
between the two groups. 
 
There was no significant difference in the baseline insulin concentration 
between the two groups. However, after consuming the mixed meal, the MMT 
Hypo group had a significantly higher mean peak serum insulin concentration 
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(Peak insulin 197.8±39.2 [MMT Hypo group] vs 103.8±23.3 [MMT Non-Hypo 
group] P<0.05). 
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Table 4.7 Prevalence of hypoglycaemia  and nadir glucose during either a 
MMT or POGTT. 16 subjects had a MMT whilst only 13 had a POGTT. 
Abbreviations, N/A- not applicable (subject did not have a POGTT) 
 
Patient No. 
MMT POGTT 
Hypo or Non-
Hypo 
Nadir glucose 
(mmol/l) 
Hypo or Non-Hypo Nadir glucose 
(mmol/l) 
1 Non-Hypo 3.7 N/A N/A 
2 Hypo 2.0 Hypo 1.7 
3 Hypo 1.7 N/A N/A 
4 Non-Hypo 3.5 Hypo 2.2 
5 Non-Hypo 3.9 Non-hypo 3.0 
6 Non-Hypo 4.3 Non-hypo 3.4 
7 Hypo 2.5 Hypo 1.7 
8 Hypo 2.8 N/A N/A 
9 Non-Hypo 4.6 Non-hypo 3.4 
10 Non-Hypo 3.8 Hypo 2.3 
11 Non-Hypo 3.9 Hypo 2.3 
12 Non-Hypo 4.7 Hypo 2.9 
13 Hypo 2.9 Non-hypo 3.8 
14 Non-Hypo 3.4 Hypo 2.8 
15 Hypo 2.5 Hypo 2.2 
16 Non-Hypo 3.6 Hypo 2.8 
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Figure 4.2 Changes in glucose (A) and insulin (B) following a mixed meal 
test in patients with suspected  PPH. Patients classified as either  hypo   (n=6) 
or non hypo (n=10), depending if their nadir  glucose was less than 3 mmol/l. 
Significant differences are **P<0.01, ***P<0.0001. 
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Outcome measures MMT Hypo 
 (N=6) 
MMT Non Hypo 
(N=10) 
Mean peak glucose (mmol.l-
1) 
8.90±0.90 10.31±1.04 
Mean nadir glucose 
(mmol.l-1) 
2.40±0.19 3.94±0.14* 
Mean time to peak glucose 
(min) 
30.00±0.00 39.00±4.58 
Mean time to nadir glucose 
(min) 
95.00±9.22 177.00±17.58* 
Glucose30 (mmol.l
-1) 8.90±0.90 9.64±1.18 
Mean peak insulin (mU.l-1) 
197.80±39.17 103.78±23.22 
Mean time to Peak insulin 
(mins) 
30.00±0.00 45.00±6.71 
Insulin 30 (mU.l
-1) 162.1±45.94 103.1±19.16* 
Mean AUC glucose (mmol.l-
1.min) 
1131.33±39.10 1429.50±111.22 
Mean AUC insulin (mU.l-
1.min) 
9325.17±1529.82 7113.20±1300.73 
Mean AUCinsulin:glucose 
(mU.mmol-1) 
8.15±1.38 5.14±0.98 
Mean Insulinogenic index 
(mU.mmol-1) 
53.85±17.19 21.70±6.24 
Table 4.8 Comparison of measures of glucose homeostasis following a 
mixed meal in PPH patients. The symptomatic RYGB patients were 
further categorised into two groups, those who had biochemical 
hypoglycaemia (MMT Hypo) and those that did not (MMT Non-Hypo) 
Significant differences are * P < 0.05. 
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4.4.3 Investigation into changes in gut hormones in PPH 
patients: Hypo vs Non-Hypo groups   
There was no significant difference in the baseline plasma GLP-1 levels 
prior to the MMT in both group (Figure 4.3). GLP-1 concentration 
following a mixed meal rose in both groups and after 30 minutes there 
was a significant difference (GLP-130 70.9±13.2 [MMT Hypo group] vs 
40.3±9.4 pmol/l [MMT Non-Hypo group] P<0.05). By 60 minutes and 
for the remainder of the MMT there was no difference in the 
concentration of GLP-1 between the groups.  
 
Baseline fasting glucagon levels were not significantly different between 
the PPH Hypo group and the PPH Non-Hypo group. Following the MMT 
glucagon concentration increased in both groups but was significantly 
higher in the PPH Hypo group at 30 and 60 minutes following 
consumption of the MMT (glucagon30 41.4±8.6 [MMT Hypo group] vs 
22.5±3.4pmol/l [MMT Non-Hypo group] P<0.05, glucagon60 38.2±10.7 
[MMT Hypo group] vs 18.8±1.9 [MMT Non-Hypo group] P<0.05). 
 
PYY and GIP concentrations rose after consumption of the mixed meal. 
The post prandial concentration of PPY and GIP in both groups peaked at 
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30 minutes. There was no significant difference in concentrations of PYY 
and GIP at any time point during the mixed meal between both groups. 
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 Figure 4.3 Changes in serum GLP-1 (A), glucagon (B), PYY (C) and 
GIP (D) following a mixed meal test. Patients classified as either  MMT 
Hypo (N=6) or MMT Non-Hypo (N=10), depending if their nadir glucose 
was less than 3 mmol/l. Significant differences are * P < 0.05. 
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4.4.4 Investigation into changes in glucose and insulin 
following a POGTT in patients with PPH. 
Only 13 of the 16 patients suspected to have PPH completed the POGTT. 
Of those 13 subjects, 9 had evidence of biochemical hypoglycaemia 
(Table 4.7). Similarly, to the previous experiment using a MMT, the 
subjects were divided into two groups based on the presence of 
biochemical hypoglycaemia; POGTT Hypo and POGTT Non-Hypo. 
 
The glucose and insulin profiles of these subjects are shown in Figure 4.4 
and Table 4.9. Both groups had a similar baseline glucose prior to 
drinking the oral glucose challenge. After consumption, the plasma 
glucose rose in both groups. The PPH Non-Hypo group had a peak 
glucose that appeared to be later than the PPH Hypo group but this was 
not statistically significant.  
 
As expected, the nadir glucose was significantly lower in the PPH Hypo 
group (nadir glucose: 2.39±0.19 [POGTT Hypo group] vs 3.40±0.16 
mmol/l [POGTT Non-Hypo group] P<0.01). 
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Figure 4.4 Changes in glucose (A) and insulin (B) during a POGTT. 
Patients were classified as either hypo (N=9) or non hypo (N=6). 
Significant differences are *   P < 0.05. 
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 Table 4.9 Comparison of measures of glucose homeostasis following a 
POGGT in PPH patients. The symptomatic RYGB patients were further 
categorised into two groups, those who had biochemical hypoglycaemia 
(POGTT Hypo) and those that did not (POGTT Non-Hypo) Significant 
differences are * P < 0.05 
  
Outcome measures POGTT Hypo (N=9) POGTT Non-Hypo  
(N=4) 
Mean peak glucose (mmol.l-
1) 
14.51±1.50 15.90±1.95 
Mean nadir glucose 
(mmol.l-1) 
2.34±0.17 
 
3.45±0.17* 
 
Mean time to peak glucose 
(min) 41.25±5.49 67.50±14.36 
Mean time to nadir glucose 
(min) 146.25±14.39 195.00±19.37 
Glucose30 (mmol.l
-1) 
13.79±1.67 10.33±1.24 
Mean Peak Insulin  (mU.l-1) 
202.70±44.70 114.27±17.14* 
Mean time to Peak insulin 
(mins) 48.75±7.89 52.50±7.50 
Insulin 30 (mU.l
-1) 162.1±45.94 103.1±19.16* 
Mean AUC glucose (mmol.l-
1.min) 
1131.33±39.10 1429.50±111.22 
Mean AUC insulin (mU.l-
1.min) 
167.00±51.79 77.83±6.80 
Mean AUCinsulin:glucose 
(mU.mmol-1) 
7.80±1.50 5.25±0.81 
Mean Insulinogenic index 
(mU.mmol-1) 
45.62±32.42 17.52±2.31 
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4.4.5 Investigation into changes in gut hormones following a 
POGTT in patients with Hypo and without Hypo during the 
test 
There was no significant difference in baseline GLP-1 between the 
groups (Figure 4.5). Following the oral glucose challenge GLP-1 rose in 
both groups. The peak concentration of GLP-1 was significantly higher in 
the POGTT Non-Hypo group (Peak GLP-1: 63.13±14.91  [POGTT Non-
Hypo group] vs 25.31±6.78 pmol/l [POGTT Hypo group] P<0.0001). 
GLP-1 concentrations returned to baseline at 180 minutes post 
consummation of the oral glucose challenge. 
 
Fasting glucagon levels were not significantly different between either 
group. Following the oral glucose challenge test, glucagon concentrations 
fluctuated but did not change significantly from the baseline levels.  
 
GIP and PYY baseline concentrations rose after consumption of the oral 
glucose challenge, before returning back to baseline by 180 minutes. 
There was no significant difference in concentration between the two 
groups at any time point. 
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Figure 4.5 Changes in GLP-1 (A), glucagon (B), GIP (C) and PYY (D) 
following an oral glucose challenge. Patients were classified as either POGTT 
Hypo (N=9) or POGTT Non-Hypo (N=4). Significant differences are * P< 0.005, 
**P<0001. 
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4.5 Discussion 
In this investigation I have demonstrated the following  
1. Subjects with PPH have increased glycaemic variability on 
continuous glucose monitoring relative to the normal ranges 
observed in a non-diabetic population.  
2. After RYGB, subjects have altered glycaemic tolerance (measured 
by a MMT) relative to an obese population. 
3. Subjects who have PPH and have biochemical hypoglycaemia 
during a MMT have an associated increase in both plasma 
glucagon and GLP-1(Table 6). 
4. Subjects who have PPH and have biochemical hypoglycaemia 
during a POGTT have an associated decrease in plasma GLP-
1(Table 4.10). 
 
 GLP-1 Glucagon GIP PYY 
MMT Increased Increased No change No change 
POGTT Decreased No change No change No change 
Table 4.10 Summary of gut hormone changes in those that have 
biochemical hypoglycaemia following either a MMT or a POGTT. 
Sixteen subjects had a MMT of which 6 had biochemical hypoglycaemia. 
Twelve subjects had a POGTT of which 8 had biochemical 
hypoglycaemia. Significant differences in peak gut hormone levels 
between those that have or did not have biochemical hypoglycaemia are 
shown. 
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4.5.1 Increased Glycaemic Variability 
In this study, subjects with PPH were demonstrated to have increased 
glycaemic variability as measured by a CGM worn for five days. The 
specific modality of glycaemic variability that was increased was MAGE 
at 4.93±0.75. The normal limits of glycaemic variability (including 
MAGE) were based on data collected from 70 glycaemic individuals by 
Hill et al(240).  
 
There are at present no normal limits for glycaemic variability established 
for the RYGB population. Subsequently it is not possible to determine 
whether the changes established in this study reflect the changes caused 
by the RYGB as opposed to being specific to the PPH population. In the 
current study there was an increase in MAGE relative to asymptomatic 
subjects who had undergone RYGB but this was not statistically 
significant, which is likely due to the small cohort size.  
 
Haniare et al also demonstrated an increase in MAGE in 10 RYGB 
patients with PPH of 4.78±3.28 (242). They also reported an increase in 
SD relative to a euglycaemic group of 10 subjects (SD 1.72±1.0 [RYGB-
PPH] vs 1.94±0.61 [euglycaemic group] mmol/l, P=0.003). The SD 
determined in the current study was 2.04±0.23 mmol/l. However, whilst 
the Hainaire et al study reported the SD in their RYGB-PPH group was 
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abnormal, it is within the normal reference range reported by Hill et 
al(240). 
  
The increased glycaemic variability reported in this study and Haniare et 
al conflicts with a study by Marfella et al that demonstrated a reduction 
in MAGE after bariatric surgery (242,243). However, this conflicting 
data may be accounted by differences in methodology. Marfella et al 
studied a cohort of patients who had pancreaticobiliary diversion (an 
alternative operation to the RYGB). Furthermore, the Marfella study 
examined glycaemic variability in the in-hospital setting in contrast to the 
free-living environment that the current study examined. 
 
The clinical relevance of increased glycaemic variability remains unclear 
in the context of RYGB patients.  In patients with either type 1 or 2 
diabetes there is an association between glycaemic variability and an 
increased incidence of hypoglycaemia(244). Other studies have shown an 
association between increased glycaemic variability with diabetic 
microvascular complications, cardiovascular disease and poor quality of 
life(245-247). Furthermore, short term studies investigating glycaemic 
variability in non-diabetic patients have shown an association with 
cardiovascular mortality and increased glycaemic variability(248).  
Whilst these findings have not been investigated in the RYGB population 
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it is noteworthy that the complications associated with increased 
glycaemic variability are at odds with the improved cardiovascular 
outcomes reported after bariatric surgery(38). 
 
There was no significant difference in the percentage time spent 
hypoglycaemic between the symptomatic and asymptomatic subjects. 
This may reflect the small numbers of subjects analysed but would 
suggest that the key difference between the groups is the perception of 
hypoglycaemia. This observation is supported by a study by Laurenius et 
al that compared the frequency of hypoglycaemic symptoms between 
symptomatic and asymptomatic subjects who underwent a mixed meal 
test(237). Laurenius et al found that whilst there was no significant 
difference in the rate of hypoglycaemia, but that the symptomatic group 
had more symptoms of hypoglycaemia. 
 
4.5.2 Altered glucose tolerance in patients post RYGB 
measured by a MMT 
This study has demonstrated that patients post RYGB have an altered 
glucose tolerance relative to a control group of obese euglycemic 
individuals, regardless of whether they are symptomatic or asymptomatic 
from PPH. The altered glucose tolerance is characterised by significantly 
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earlier and higher glucose peak concentration following consumption of a 
mixed meal. This data is consistent with previous reports(230). 
 
The higher peak concentration of glucose in the RYGB patients is in 
keeping with their increased glycaemic variability. Whilst all RYGB 
patients had normal glycated haemoglobin, the elevated postprandial 
glucose levels invites speculation as to whether they are at increased risk 
of diabetic complications. Whilst the SOS study demonstrated an 
improvement in macrovascular complications, smaller studies have 
demonstrated conflicting data on the improvement in microvascular 
complications(249-251). The SOS study which was a non-randomised 
controlled study comparing bariatric surgery to lifestyle management 
demonstrated a significant reduction in the cumulative incidence of 
microvascular events from  41.8 (control group) to 20.6 per 1000 patient-
years (bariatric surgery group(249)). Miras et al in a prospective case 
study demonstrated an improvement in nephropathy at one year post 
surgery but this was not shown for retinopathy or neuropathy(250). 
Furthermore, a recent meta-analysis investigating the effects of bariatric 
surgery on retinopathy revealed that whilst 19.2 ± 12.9 % of patients had 
improvement in their disease, 23.5±18.7 had a deterioration in 
retinopathy(251). The relevance of this data relates to how outcome 
measures after RYGB are interpreted. Many RCTs have inferred an 
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improvement in diabetic status based on a reduction in HbA1c(36,252). 
This is based on previous studies assessing intensive medical therapies 
demonstrating that reductions  in HbA1c are a reliable surrogate marker 
for improvements in diabetic complications(253,254). However, whilst 
RYGB does improve HbA1c there is also an increase in glycaemic 
variability which has been shown to be an independent risk factor for an 
increase in microvascular complications (245). Randomised controlled 
studies with long term data is needed to evaluate whether the altered 
glucose tolerance post RYGB results in better or worse microvascular 
outcomes, compared to a medically treated diabetic cohort (with a similar 
HbA1c). 
 
4.5.3 Differences in glucose, insulin and gut hormones, 
between RYGB patients who have biochemical 
hypoglycaemia and those that do not, during a MMT 
 
This study demonstrated no significant difference in the peak glucose 
concentrations between RYGB patients that had hypoglycaemia and 
those that did not. However, the patients that subsequently had 
hypoglycaemia had a significantly higher insulin peak. The increased 
insulin response to glucose is associated with a higher GLP-1 and 
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glucagon concentration.  An elevated concentration of both GLP-1 and 
glucagon post RYGB after consumption of a mixed meal is consistent 
with previous reports(73,74,183). However, whilst an increased GLP-1 
secretion has been implicated in the pathology of PPH, increased 
glucagon secretion has not. Both hormones are insulinotropic and so 
could be responsible for the increased insulin peak observed in PPH 
patients.  
 
Elevated postprandial plasma glucagon is considered paradoxical and is 
associated with diabetes(255). The source of glucagon has been 
previously been ascribed to the pancreas but a recent study by Holst et al 
have demonstrated extra-pancreatic glucagon secretion in patients who 
have had pancreatectomies(256). Holst et al speculate that the elevated 
glucagon may originate from L cells with aberrant processing of 
proglucagon. As there is hyperplasia of L cells after RYGB, as well as 
hyper-secretion of other hormones such as GLP-1 from these 
enteroendocrine cells it is possible that they account for the elevated 
postprandial glucagon levels(177,179,257). One method to asses this 
would be to perform pancreatectomies in rodent models of RYGB to 
investigate whether the observed elevated postprandial glucagon persists. 
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The relative contribution of GLP-1 and glucagon to the elevated insulin 
and subsequent hypoglycaemia remains unclear. There is conflicting data 
on the role of GLP-1 in PPH. Goldfine et al have demonstrated that 
patients with PPH have higher concentrations of GLP-1 than obese and 
symptomatic RYGB controls(184). Furthermore Salehi et al have 
previously shown that an infusion of a GLP-1 receptor antagonist 
(Exendin 9-39) during a mixed meal test in patients with  PPH 
ameliorated the hypoglycaemia(235). However, in contrast to the above 
findings, surgical reversal of RYGB reduces the elevated GLP-1 
concentration in PPH patients to presurgical levels but does not cure them 
of their hypoglycaemia(258). In contrast to the findings of Salehi et al, 
another group have demonstrated that GLP-1 receptor agonists can 
successfully treat PPH suggesting that GLP-1 action may be of benefit in 
this disease(191). 
  
The mechanism by which GLP-1 receptor agonists ameliorate PPH has 
not been confirmed. GLP-1’s known actions of reducing gastric emptying 
and increasing glucose-dependent insulin secretion are unlikely to 
contribute to its beneficial effect in  patients with PPH(259). Post RYGB, 
patient have a small gastric pouch which rapidly empties and so is 
unlikely to be affected by GLP-1. Any insulinotropic action of GLP-1 
would likely make hypoglycaemia worse and hence, it is counterintuitive 
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that a GLP-1 agonist could improve PPH.  However, its glucagonostatic 
action may be relevant based on the current study’s finding of elevated 
glucagon concentration in the MMT Hypo patients. GLP-1 is known to 
potently inhibit glucagon secretion independently of its action on insulin 
secretion(260). Pancreatic β cells have glucagon receptors and cell 
studies have demonstrated that glucagon stimulates glucose dependent 
insulin secretion(261). The presence of a glucagon antagonist resulted in 
a 51±6% reduction in insulin secretion(261). This data supports the 
potential role of glucagon in the elevated postprandial insulin levels 
observed in PPH. Further evaluation is needed to determine whether 
GLP-1 receptor agonist treatment results in reduced glucagon 
concentration in PPH patients. 
 
4.5.4 Comparison of glucose, insulin and gut hormone 
responses between a MMT and POGTT in patients with 
PPH. 
 
More of the PPH patients demonstrated biochemical hypoglycaemia 
following consumption of an oral glucose challenge (9/13 or 69%) 
compared to a mixed meal stimulus (6/16 or 37.5%). Interestingly, in 
contrast with the MMT study, in those PPH patients who had biochemical 
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hypoglycaemia during the POGTT, there was a significant reduction in 
GLP-1 concentration. Furthermore, there was no significant increase in 
glucagon concentration following consumption of the oral glucose 
challenge in either the hypoglycaemic or non-hypoglycaemic group, in 
contrast to the situation with the MMT where we found an increased 
post-prandial secretion of glucagon in the hypoglycaemic group. The 
relatively high prevalence of hypoglycaemia following a oral glucose 
challenge relative to a mixed meal supports the notion that a diet that uses 
carbohydrates with low glycemic index may benefit patients with 
PPH(262).  
 
The differences noted above may relate to differences in the stimulus 
used in either provocation test.  The mixed meal provocation test uses a 
mixture of fat (20%), protein (16%) and carbohydrate (64%) whilst the 
POGTT uses 75 g of anhydrous glucose. In addition to the disparity in 
macronutrients, there are also differences in total calorie content (290 
calories in POGTT and 330 calories in the MMT) and volume (500 ml in 
the POGTT and 220 ml in the MMT). 
 
The stimulus used in the POGTT results in faster absorption of glucose 
by the intestine into the blood stream.  This is reflected in the higher peak 
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glucose observed in the POGGT relative to the MMT (Peak glucose 
15.02±1.16  [POGTT] vs 9.78±0.73 mmol/l [MMT] P<0.001). 
 
The absence in any rise in glucagon concentration following the POGTT 
is likely due to the absence of protein as amino acids are a potent 
stimulus for glucagon secretion. Fat also causes an increase in glucagon 
concentration but less so than protein(263,264).  
 
The mechanisms that underlie the significant increase in GLP-1 
concentration in POGTT Non-Hypo group compared to the POGTT 
Hypo group remain unclear. This finding may be due to a type I statistical 
error due to the low number of subjects in the POGTT Non-Hypo group.  
Few studies have used an oral glucose stimulus, opting instead for a 
mixed meal test. However, those that have used a POGTT have 
demonstrated an increase in GLP-1 albeit with an even smaller number of 
subjects studied than the current study (265). 
 
Also, the subdivision of subjects into those that have hypoglycaemia and 
those that do not is based the premise that in the absence of 
hypoglycaemia, there is no associated abnormal gut hormone response 
beyond what is observed after RYGB. However, if the above premise is 
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not true, the POGTT Non-Hypo group would not be an appropriate 
control group. 
 
A further study with larger numbers of subjects and a separate control 
group of RYGB subjects who have no symptoms of PPH may help to 
explain the findings from the POGTT study.  A larger cohort size would 
increase the power of the study.  
 
The observations in this study have been made based on a single 
provocation test and should be interpreted with caution regarding the 
reproducibility of the provocation tests. Specifically, the oral glucose 
tolerance test has been shown to have variable results on repeat 
testing(266-268). Hence, a subject who is known to have PPH may have 
biochemical hypoglycaemia following a single provocation test but this 
may not occur on repeat testing and vice versa. To make the study 
tractable, I classified the subject as having PPH if they had biochemical 
hypoglycaemia following provocation regardless of their previous 
history. An alternative method would be to repeat MMTs or POGTT on 
each individual subject and correlate gut hormone levels to their glucose 
status. However, the symptoms of PPH after provocation are difficult to 
tolerate and subsequently it may be difficult to recruit for multiple 
provocation tests. 
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 In conclusion, these studies have demonstrated a number of significant 
findings in the hormonal fluxes that occur in PPH. GLP-1, which is 
thought to underlie many of the improvements in glucose tolerance post 
RYGB, may also play a role in the pathogenesis of PPH. Furthermore, 
changes in glucagon secretion may also be important. A greater 
understanding of the roles of these hormones could help treat PPH 
patients as well as to guide future medical treatment for obesity based on 
gut hormones.  
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Chapter 5      
 General Discussion 
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The prevalence of obesity has rapidly risen such that 25% of the UK adult 
population is now obese(269). The cost of obesity can be measured both 
to the individual in terms of associated medical conditions and to society 
with respect to the costs of treating obesity.  
 
Obesity is associated with a variety of medical conditions including 
T2DM, ischaemic heart disease, OSA, hypertension and cancer(270). The 
cumulative health burden associated with obesity is reflected in the  50% 
higher mortality risk in young adults with obesity relative to those who 
are overweight(271). For society the economic burden to the NHS, from 
treating overweight and obese individuals is £5.1 billion(272). 
Worryingly, the prevalence of childhood obesity continues to rise, which 
forebodes an ever increasing health burden unless suitable, effective 
treatments are achieved(273).  
 
Currently, the most effective treatment for obesity is bariatric surgery 
resulting in sustained weight loss and improvements in obesity related co-
morbidities up to 20 years later(38). The weight loss observed after 
RYGB surgery is greater than either of the currently available anti-
obesity therapeutics; orlistat (GlaxoSmithKline, London UK)  or 
liraglutide (NovoNordisk, Denmark)(17,38,123).  
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Orlistat is an intestinal lipase inhibitor(274). Weight loss with orlistat is 
significant but modest; at one year a systematic review showed 3.5% 
greater weight loss than placebo(17). The XENDOS study (which had a 
longer follow up of four years) revealed weight loss of 2.4% greater than 
placebo(275). This study also illustrated that the significant 
gastrointestinal side effect profile of orlistat which resulted in a 48% 
attrition rate(275). 
  
Liraglutide is more effective, achieving 5.4 % greater weight loss than 
placebo at one year(123). This anti-obesity medication is based on a gut 
hormone, GLP-1, that has multiple beneficial metabolic actions including 
an insulinotrophic effect, a delay in gastric emptying, a reduction in food 
intake and an increase in satiety.  It is also one of a series of hormones 
(including glucagon, OXM and PYY) whose postprandial concentration 
is increased after RYGB surgery(180). Whilst the weight loss observed 
with liraglutide is lower that than observed after RYGB, the use of 
additional  gut hormones combined with a GLP-1 agonist may result in 
greater weight loss.  
 
A series of studies have explored the benefits of dual infusion of gut 
hormones on food intake. Human infusion studies have demonstrated that 
combining GLP-1 with PYY, OXM or glucagon has an additive anorectic 
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effect(201,218,276). However, there are no data on the effects of 
combined infusions on glucose tolerance, nor the effects on food take by 
the co-infusion of three hormones. This thesis builds on these previous 
studies,  further investigating the co-infusion of GLP-1 and glucagon, but 
also focusing on their effects on glucose tolerance. It also investigates the 
effects of a triple hormone infusion on food intake in man. The studies 
were designed to use hormone doses that would replicate the levels 
observed following RYGB to assess the contribution that these hormones 
have on food intake and glucose tolerance as well as to explore their use 
as an anti-obesity treatment. Furthermore, the role of gut hormones in the 
pathology of a PPH (a complication of RYGB) has been investigated to 
address potential safety issues of raised gut hormones after RYGB.  
 
Co-infusion of GLP-1, OXM and PYY on food intake in man. 
In chapter 3, I have demonstrated for the first time that co-infusion of 
GLP-1, oxyntomodulin and PYY resulted in a reduction in food intake 
relative to saline. The novelty of this study is two-fold. Firstly, it 
represents the first in man infusion of three gut hormones. Secondly, 
whilst GLP-1 has been previously delivered via a SC pump, 
oxyntomodulin and PYY have not. 
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The latter is particularly relevant to the feasibility of this treatment being 
used for obese patients. Previous co-infusions of gut hormones have been 
characterised by being intravenous as well as acute (lasting from 90 to 
240 minutes and only using one ad-libitum meal) whilst the current study 
used a 14 hour infusion and assessed food intake over two meals. Given 
that gut hormones have a short half life ranging from 4-12 minutes, an 
appropriate drug delivery system has to be used(142,277,278). Evidence 
that a continuous subcutaneous pump would be acceptable for patients is 
their current use in the treatment of T1DM and Parkinson’s 
disease(221,222). An alternative method of administering gut hormones 
is the use of long acting analogues. However, whilst there are numerous 
types of GLP-1 based analogues, there are no commercially available 
long acting agonists at the PYY or OXM receptors, although these are in 
phase I development(279-281).   
 
The triple hormone infusion of OXM, GLP-1 and glucagon did not alter 
plasma glucose or serum insulin concentrations relative to saline.  As 
subjects were given ad-libitum meals, it is not possible to comment on 
post-prandial glucose concentrations due to the confounding effects of 
different energy intake. However, there was no difference in the pre-
prandial glucose concentrations between the triple hormone and saline 
infusion arms. Nuack et al  using an intravenous infusion of GLP-1 (1.2 
 188 
pmol/kg/min) demonstrated a  significant reduction in fasting glucose 
concentration in subjects with insulin-treated T2DM(282). Furthermore, 
in chapter 2, an intravenous infusion of 0.4 pmol/kg/min resulted in a 
significant reduction in pre-prandial glucose concentrations. However, 
Toft-Nielsen et al using a dose of subcutaneous GLP-1 (2.4 pmol/kg/min) 
in subjects with non-insulin dependent T2DM found no significant effect 
on fasting glycaemia(283). The disparity between the studies may be 
accounted by the glycaemic status of the subjects. Alternatively,  in the 
study by Nauck et al the intravenous infusion of GLP-1 resulted in a 
significant reduction in plasma glucagon concentrations whilst the study 
by Toft-Nielsen et al did not. An elevated plasma glucagon concentration 
is observed in T2DM and may  partly account for the hyperglycaemia 
seen in this disease(70). This is supported by the finding in chapter 2, in 
which the infusion of glucagon resulted in higher pre-prandial glucose 
concentrations.  
  
5.1 Co-infusion of GLP-1 and glucagon on 
carbohydrate tolerance in man. 
In chapter 2, I demonstrated that the addition of GLP-1 to glucagon 
infusion in humans attenuated the post-prandial insulinotrophic effect of 
glucagon alone. Furthermore, the infusion of GLP-1 alone results in a 
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lower postprandial insulin response compared to vehicle. This conflicts 
with data demonstrating that  both glucagon and GLP-1 stimulate insulin 
release via their respective receptors on pancreatic β-cells(284-286). The 
attenuated postprandial insulin concentration observed with GLP-1 alone 
is potentially due to its effect on delaying gastric emptying(101).  
 
In contrast with the findings above, the elevated post-prandial insulin 
observed in subjects with PPH was associated with raised GLP-1 
concentrations. This disparity may be due to the changes to the 
mechanical properties of the stomach after RYGB. After RYGB, patients 
have a smaller gastric pouch with no pylorus resulting in rapid gastric 
pouch emptying.  Hence, any effect of GLP-1 on attenuation serum 
insulin concentrations due to gastric emptying in the post RYGB patients, 
may be outweighed by its insulinotrophic effects. 
  
In chapter 4, RYGB patients with hypoglycemia had higher peak 
postprandial insulin concentrations and subsequent lower plasma glucose 
concentrations. Hypoglycemia was also associated with higher levels of 
both GLP-1 and glucagon. Co-infusion of GLP-1 and glucagon in chapter 
2, did result in a lower AUC glucose relative to placebo, but there was no 
evidence of hypoglycemia (blood glucose less than 4.0 mmol/L). The 
absence of hypoglycemia observed in the infusion studies may reflect the 
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small cohort size, the relatively lower concentrations of GLP-1 and 
glucagon or the difference between infusions delivered in the short-term 
and the chronic elevation of hormones observed after RYGB. This latter 
factor may be relevant as studies with follow up of patients receiving 
long-term  administration of GLP-1 have shown an increase in the 
incidence of hypoglycemia relative to placebo(123,287). Furthermore, 
tumours that secrete GLP-1 have been associated with reactive 
hypoglycemia(288,289). 
 
There are at present no human studies investigating the effects of chronic 
administration of glucagon. Tumours that secrete glucagon are generally 
associated with hyperglycemia and diabetes(290).However, there is a 
case report of a patient with a glucagonoma presenting with 
hypoglycemia suggesting that glucagon could be implicated in 
PPH(291).There has also been one case report of a patient with a tumour 
that co-secreted both GLP-1 and glucagon that presented with both hypo- 
and hyperglycemia(289). It is possible that in the former case report by 
Bolt et al, the tumour was co-secreting GLP-1 with glucagon as no GLP-
1 assay was performed. 
 
The association of elevated glucagon with hypoglycemia is counter-
intuitive as whilst glucagon is known to be insulinotrophic, it is also 
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considered a counter-regulatory hormone to insulin and is used in the 
treatment of hypoglycemia. Glucagonincreases plasma glucose levels by 
promoting gluconeogenesis and glycogenolysis(292). One possible 
mechanism by which elevated glucagon concentration post RYGB may 
result in hypoglycemia is through tachyphylaxis. Tachyphylaxis is the 
process by which repeated administration of a ligand results in a 
reduction in effect and has been observed with glucagon in the context of 
hepatic glycogenolysis(293). It is possible that the significantly elevated 
glucagon concentrations observed in patients with PPH results in 
tachyphylaxis such that the effect of glucagon on glycogenolysis is 
attenuated, resulting in hypoglycemia in the context of elevated insulin. 
This hypothesis could be investigated using animal studies in which 
insulin is administered to mice that have been receiving a  continuous 
infusion of glucagon or saline, at various durations, to assess the presence 
of hypoglycemia. The duration of glucagon infusion in which 
hypoglycemia occurs would provide information as to the timing at 
which tachyphylaxis occurs. Furthermore, if hypoglycemia does occur, 
the study could be repeated after a period in which the glucagon infusion 
has been stopped to determine if the tachyphylaxis is reversible.     
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5.2 Combining gut hormones as treatment for obesity  
The work presented in this thesis demonstrates that co-administration of a 
combination of gut hormones can reduce food intake (GLP-1, OXM and 
PYY) and improve glycemic control (GLP-1 and glucagon). However, 
these data result from short-term studies and prior to further development 
as anti-obesity treatments, longer duration studies are warranted.  
 
Specific hurdles to the use of gut hormones as a treatment for obesity 
include the increased incidence of nausea, potential risks of pancreatitis 
and PPH(187,294,295). In chapter 3, the dose finding part of the study 
demonstrated that GLP-1, OXM and PYY can all cause a dose-dependent 
nausea and that combining those hormones reduces the individual peptide 
dose at which nausea occurs.  Clinical trials investigating GLP-1 
analogues have demonstrated a dose-dependent relationship with nausea 
that is transient(294). Hence, there may be attenuation of nausea 
following chronic triple hormone administration.  
 
Concerns regarding the risk of pancreatitis with the use of GLP-1 
analogues in man were first raised following an analysis of the FDA’s 
database of reported adverse events(295) Subsequent analysis of 
alternative databases and meta-analysis have failed to demonstrate further 
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evidence supporting this safety concern (296,297). However, any future 
clinical research study investigating the chronic effects of administration 
of GLP-1 with OXM and PYY will likely need to monitor amylase and 
lipase (surrogates of pancreatitis) concentrations. 
 
Gut hormones, and specifically GLP-1 have been implicated in the 
pathology of PPH since its first description(232) This thesis provides 
further evidence supporting the association of GLP-1 with PPH. In 
addition it also shows an association with elevated post prandial glucagon 
levels. However, whether the relationship between PPH and elevated 
GLP-1 and glucagon is causal remains unclear. Furthermore, the use of 
GLP-1 agonists have proven helpful in the treatment of PPH(191). 
Nonetheless, further clinical trials using a triple hormone combination 
will require glucose monitoring.  
 
In conclusion, co-administration of GLP-1, OXM and PYY has been 
shown to reduce energy intake whilst GLP-1 and glucagon resulted in 
improved carbohydrate tolerance. These findings add support to the 
proposal that gut hormones have a role in the metabolic benefits observed 
after RYGB. However, further long-term studies are required to 
determine whether the acute changes observed translate to longer-term 
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improvements in metabolic status as well as to assess the incidence of 
side-effects such as nausea, pancreatitis and PPH.  
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Future work  
A study comparing the effects of RYGB surgery with those of a 
chronic infusion (28 days) of a combination of GLP-1, oxyntomodulin 
and PYY. 
Following on from the acute study demonstrating a reduction in food 
intake with the triple hormone infusion, this investigation will study the 
effects of a chronic infusion on specific outcomes that are known to 
improve after RYGB. These include, food intake, body weight, energy 
expenditure and carbohydrate tolerance. A control group consisting of 
matched subjects undergoing RYGB will be used to compare outcomes. 
The results of this study will provide information on the contribution of 
elevated gut hormones on the beneficial metabolic effects of RYGB. In 
addition, it will provide answers regarding the feasibility of delivering gut 
hormones via a subcutaneous pump and potentially represent a step closer 
to combination gut hormone therapy becoming a treatment for obesity.   
 
A randomised controlled study investigating the use of liraglutide in 
the treatment of PPH. 
The work in this thesis has shown an association between both GLP-1 
and glucagon with PPH. However, a causal link has not been established 
with both GLP-1 receptor antagonists and agonists demonstrating an 
attenuation in hypoglycaemia. The evidence regarding GLP-1 agonists is 
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limited to a case series. Hence, a randomised controlled, blinded study is 
needed to determine whether this effect is real. GLP-1 agonists suppress 
glucagon and so this study will be useful in determining the relative 
contributions of both GLP-1 and glucagon in the pathology of PPH.  
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Chapter 6     
 Appendix 
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6.1 Appendix 1- VAS  
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VISUAL ANALOGUE SCALE 
T=0           
How hungry do you feel right now? 
NOT AT ALL             EXTREMELY              
 
How sick do you feel right now? 
 NOT AT ALL              EXTREMELY        
 
How pleasant would it be to eat right now? 
NOT AT ALL              EXTREMELY 
 
How much do you think you could eat right now? 
NOTHING                        A LARGE 
AMOUNT                                                                                                                                                 
 
How full do you feel right now? 
NOT AT ALL                              EXTREMELY 
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6.2 Appendix 2- Magpix Protocol  
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